<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN"
        "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
    <article article-type="review-article" xml:lang="en" dtd-version="1.4">
        <front>
            <journal-meta>
                <journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id>
                <journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id>
                <journal-id journal-id-type="pmc-domain-id">2102</journal-id>
                <journal-id journal-id-type="pmc-domain">pharmaceuticals</journal-id>
                <journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id>
                <journal-title-group>
                    <journal-title>Pharmaceuticals</journal-title>
                </journal-title-group>
                <issn pub-type="epub">1424-8247</issn>
                <publisher>
                    <publisher-name>Multidisciplinary Digital Publishing Institute (MDPI)</publisher-name>
                </publisher>
            </journal-meta>
            <article-meta>
                <article-id pub-id-type="pmcid">PMC7696421</article-id>
                <article-id pub-id-type="pmcid-ver">PMC7696421.1</article-id>
                <article-id pub-id-type="pmcaid">7696421</article-id>
                <article-id pub-id-type="pmcaiid">7696421</article-id>
                <article-id pub-id-type="pmid">33203094</article-id>
                <article-id pub-id-type="doi">10.3390/ph13110392</article-id>
                <article-id pub-id-type="publisher-id">pharmaceuticals-13-00392</article-id>
                <article-version article-version-type="pmc-version">1</article-version>
                <article-categories>
                    <subj-group subj-group-type="heading">
                        <subject>Review</subject>
                    </subj-group>
                </article-categories>
                <title-group>
                    <article-title>Assembly of Peptidoglycan Fragments—A Synthetic Challenge</article-title>
                </title-group>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name name-style="western">
                            <surname>Queda</surname>
                            <given-names initials="F">Fausto</given-names>
                        </name>
                        <xref ref-type="aff" rid="af1-pharmaceuticals-13-00392">1</xref>
                    </contrib>
                    <contrib contrib-type="author">
                        <name name-style="western">
                            <surname>Covas</surname>
                            <given-names initials="G">Gonçalo</given-names>
                        </name>
                        <xref ref-type="aff" rid="af2-pharmaceuticals-13-00392">2</xref>
                        <xref ref-type="aff" rid="af3-pharmaceuticals-13-00392">3</xref>
                    </contrib>
                    <contrib contrib-type="author">
                        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4485-832X
                        </contrib-id>
                        <name name-style="western">
                            <surname>Filipe</surname>
                            <given-names initials="SR">Sérgio R.</given-names>
                        </name>
                        <xref ref-type="aff" rid="af2-pharmaceuticals-13-00392">2</xref>
                        <xref ref-type="aff" rid="af3-pharmaceuticals-13-00392">3</xref>
                        <xref rid="c1-pharmaceuticals-13-00392" ref-type="corresp">*</xref>
                    </contrib>
                    <contrib contrib-type="author">
                        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6712-752X
                        </contrib-id>
                        <name name-style="western">
                            <surname>Marques</surname>
                            <given-names initials="MMB">M. Manuel B.</given-names>
                        </name>
                        <xref ref-type="aff" rid="af1-pharmaceuticals-13-00392">1</xref>
                        <xref rid="c1-pharmaceuticals-13-00392" ref-type="corresp">*</xref>
                    </contrib>
                </contrib-group>
                <aff id="af1-pharmaceuticals-13-00392"><label>1</label>LAQV@REQUIMTE, Departamento de Química, Faculdade
                    de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, 2829-516 Caparica,
                    Portugal;
                    <email>f.queda@campus.fct.unl.pt</email>
                </aff>
                <aff id="af2-pharmaceuticals-13-00392"><label>2</label>UCIBIO@REQUIMTE, Departamento de Ciências da
                    Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, 2829-516
                    Caparica, Portugal;
                    <email>goncalocovas@itqb.unl.pt</email>
                </aff>
                <aff id="af3-pharmaceuticals-13-00392"><label>3</label>Laboratory of Bacterial Cell Surfaces and
                    Pathogenesis, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780-157
                    Oeiras, Portugal
                </aff>
                <author-notes>
                    <corresp id="c1-pharmaceuticals-13-00392"><label>*</label>Correspondence: <email>
                        sfilipe@fct.unl.pt
                    </email> (S.R.F.); <email>mmbmarques@fct.unl.pt</email> (M.M.B.M.)
                    </corresp>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>15</day>
                    <month>11</month>
                    <year>2020</year>
                </pub-date>
                <pub-date pub-type="collection">
                    <month>11</month>
                    <year>2020</year>
                </pub-date>
                <volume>13</volume>
                <issue>11</issue>
                <issue-id pub-id-type="pmc-issue-id">369598</issue-id>
                <elocation-id>392</elocation-id>
                <history>
                    <date date-type="received">
                        <day>06</day>
                        <month>10</month>
                        <year>2020</year>
                    </date>
                    <date date-type="accepted">
                        <day>12</day>
                        <month>11</month>
                        <year>2020</year>
                    </date>
                </history>
                <pub-history>
                    <event event-type="pmc-release">
                        <date>
                            <day>01</day>
                            <month>11</month>
                            <year>2020</year>
                        </date>
                    </event>
                    <event event-type="pmc-live">
                        <date>
                            <day>29</day>
                            <month>11</month>
                            <year>2020</year>
                        </date>
                    </event>
                    <event event-type="pmc-last-change">
                        <date iso-8601-date="2020-11-30 18:56:19.270">
                            <day>30</day>
                            <month>11</month>
                            <year>2020</year>
                        </date>
                    </event>
                </pub-history>
                <permissions>
                    <copyright-statement>© 2020 by the authors.</copyright-statement>
                    <copyright-year>2020</copyright-year>
                    <license license-type="open-access">
                        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining"
                                         content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/
                        </ali:license_ref>
                        <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed
                            under the terms and conditions of the Creative Commons Attribution (CC BY) license
                            (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri"
                                       xlink:href="http://creativecommons.org/licenses/by/4.0/">
                                http://creativecommons.org/licenses/by/4.0/</ext-link>).
                        </license-p>
                    </license>
                </permissions>
                <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf"
                          xlink:href="pharmaceuticals-13-00392.pdf"/>
                <abstract>
                    <p>Peptidoglycan (PGN) is a major constituent of most bacterial cell walls that is recognized as a
                        primary target of the innate immune system. The availability of pure PGN molecules has become
                        key to different biological studies. This review aims to (1) provide an overview of PGN
                        biosynthesis, focusing on the main biosynthetic intermediates; (2) focus on the challenges for
                        chemical synthesis posed by the unique and complex structure of PGN; and (3) cover the synthetic
                        routes of PGN fragments developed to date. The key difficulties in the synthesis of PGN
                        molecules mainly involve stereoselective glycosylation involving NAG derivatives. The complex
                        synthesis of the carbohydrate backbone commonly involves multistep sequences of chemical
                        reactions to install the lactyl moiety at the O-3 position of NAG derivatives and to control
                        enantioselective glycosylation. Recent advances are presented and synthetic routes are described
                        according to the main strategy used: (i) based on the availability of starting materials such as
                        glucosamine derivatives; (ii) based on a particular orthogonal synthesis; and (iii) based on the
                        use of other natural biopolymers as raw materials.
                    </p>
                </abstract>
                <kwd-group>
                    <kwd>bacterial peptidoglycan</kwd>
                    <kwd>PGN biosynthesis</kwd>
                    <kwd>PGN synthesis</kwd>
                    <kwd>NAG-NAM disaccharide</kwd>
                </kwd-group>
                <custom-meta-group>
                    <custom-meta>
                        <meta-name>pmc-status-qastatus</meta-name>
                        <meta-value>0</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-status-live</meta-name>
                        <meta-value>yes</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-status-embargo</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-status-released</meta-name>
                        <meta-value>yes</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-open-access</meta-name>
                        <meta-value>yes</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-olf</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-manuscript</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-legally-suppressed</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-has-pdf</meta-name>
                        <meta-value>yes</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-has-supplement</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-pdf-only</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-suppress-copyright</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-is-real-version</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-is-scanned-article</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-preprint</meta-name>
                        <meta-value>no</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-prop-in-epmc</meta-name>
                        <meta-value>yes</meta-value>
                    </custom-meta>
                    <custom-meta>
                        <meta-name>pmc-license-ref</meta-name>
                        <meta-value>CC BY</meta-value>
                    </custom-meta>
                </custom-meta-group>
            </article-meta>
        </front>
        <body>
            <sec sec-type="intro" id="sec1-pharmaceuticals-13-00392">
                <title>1. Introduction</title>
                <p>Peptidoglycan (PGN) is a major component of the cell wall that surrounds most bacteria. It is a
                    macromolecule made of glycan chains, which consist of linear alternating copolymers of β-1,4-linked <italic
                            toggle="yes">N</italic>-acetyl glucosamine (GlcNAc or NAG) and <italic toggle="yes">
                        N</italic>-acetyl muramic acid (MurNAc or NAM) residues. Importantly, these glycan strands carry
                    a lactyl group in the MurNAc moiety that is covalently bound to peptide stems via an amide bond.
                    These stems are used to link glycan strands that are nearby, creating a net-like structure. The
                    composition of the peptide stems is specific for each bacterial species (<xref ref-type="fig"
                                                                                                   rid="pharmaceuticals-13-00392-f001">
                        Figure 1</xref>) [<xref rid="B1-pharmaceuticals-13-00392" ref-type="bibr">1</xref>]. The
                    unbranched peptide stems are typically pentapeptides of alternating L- and D-amino acids, usually
                    L-alanine, D-glutamic acid, a diamino acid and two terminal D-alanines. The diamino acid in the
                    third position is usually <italic toggle="yes">meso</italic>-diaminopimelic acid (DAP) in
                    Gram-negative bacteria and <sc>l</sc>-Lysine is Gram-positive [<xref
                            rid="B2-pharmaceuticals-13-00392" ref-type="bibr">2</xref>]. The diamino acids in the
                    peptide stems allow PGN to “branch out” and connect to neighboring peptide stems, cross-linking
                    adjacent glycan chains [<xref rid="B2-pharmaceuticals-13-00392" ref-type="bibr">2</xref>].
                </p>
                <p>Bacterial PGN, a telltale molecule recognized by the innate immune system from different organisms,
                    has important functions for the survival of bacteria. The structure of the PGN macromolecule
                    determines the shape of these microorganisms; anchors different proteins, which are required for
                    bacteria to interact with the surrounding environment and for the maintenance of envelope integrity;
                    and provides the required mechanical strength to resist osmotic pressure [<xref
                            rid="B2-pharmaceuticals-13-00392" ref-type="bibr">2</xref>]. Importantly, modification of
                    the bacterial process of PGN synthesis, or of PGN composition, can be associated with an altered
                    expression of resistance to different antibiotics. Examples of this effect include resistance to
                    beta-lactams in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)
                    strains, which is dependent on expression of different PGN synthetic enzymes [<xref
                            rid="B3-pharmaceuticals-13-00392" ref-type="bibr">3</xref>], as well as resistance to
                    vancomycin in isolates of <italic toggle="yes">Enterococcus</italic> species, which requires
                    modification of the PGN precursors to reduce the affinity of the antibiotic to its target [<xref
                            rid="B4-pharmaceuticals-13-00392" ref-type="bibr">4</xref>].
                </p>
                <p>PGN metabolism requires (i) the synthesis of PGN building blocks inside bacteria (also known as
                    muropeptide precursors), (ii) their transport across the bacterial membrane, (iii) the
                    polymerization of the PGN scaffold, and (iv) the trimming or degradation of the PGN molecule. These
                    processes take place during the bacterial cell cycle and ensure that PGN, which is a dynamic
                    structure, is remodeled during bacterial growth.
                </p>
                <p>Antibiotics that block PGN synthesis or that lead to changes in the composition of the bacterial cell
                    surface may weaken the cell wall (for example by decreasing the number of crosslinking nodes between
                    different glycan chains and reducing the robustness of the macromolecule to environment insults),
                    lead to alterations of the bacterial shape, and, ultimately, cause bacterial death. Loss of
                    viability may also result from cell lysis, due to the promoted activity of PGN hydrolases [<xref
                            rid="B5-pharmaceuticals-13-00392" ref-type="bibr">5</xref>,<xref
                            rid="B6-pharmaceuticals-13-00392" ref-type="bibr">6</xref>] or due to futile cycling of PGN
                    synthesis and degradation, which depletes cellular resources [<xref
                            rid="B7-pharmaceuticals-13-00392" ref-type="bibr">7</xref>]. PGN hydrolases, or ‘‘lysins’’,
                    are capable of degrading the bacterial cell wall [<xref rid="B8-pharmaceuticals-13-00392"
                                                                            ref-type="bibr">8</xref>]. Lysins can (i)
                    act on the sugar moiety, releasing either glycan fragments with NAG at the reducing end
                    (endo-β-<italic toggle="yes">N</italic>-acetylglucosaminidases) or glycan fragments with NAM at the
                    reducing end (<italic toggle="yes">N</italic>-acetylmuramidases, also known as lysozymes); (ii) act
                    on the peptide moiety (endopeptidases or carboxypeptidases); (iii) hydrolyze the amide bond linking
                    the lactyl group of NAM residues to the peptide stem (N-acetylmuramoyl-<sc>l</sc>-alanine amidases)
                    [<xref rid="B6-pharmaceuticals-13-00392" ref-type="bibr">6</xref>,<xref
                            rid="B7-pharmaceuticals-13-00392" ref-type="bibr">7</xref>,<xref
                            rid="B8-pharmaceuticals-13-00392" ref-type="bibr">8</xref>].
                </p>
                <p>Despite advances in the understanding of PGN biosynthesis and its inhibition by antibiotics, the
                    study of the relevance of PGN structure in bacterial metabolism and of its role in host disease has
                    been hampered by the lack of pure PGN fragments [<xref rid="B9-pharmaceuticals-13-00392"
                                                                           ref-type="bibr">9</xref>].
                </p>
                <p>Chemical synthesis of NAG containing oligosaccharides [<xref rid="B10-pharmaceuticals-13-00392"
                                                                                ref-type="bibr">10</xref>,<xref
                        rid="B11-pharmaceuticals-13-00392" ref-type="bibr">11</xref>,<xref
                        rid="B12-pharmaceuticals-13-00392" ref-type="bibr">12</xref>,<xref
                        rid="B13-pharmaceuticals-13-00392" ref-type="bibr">13</xref>], such as the NAG-NAM disaccharide,
                    is a challenging task due to well-known limitations associated with the enantioselective
                    glycosylation of NAG moieties: (i) the presence of a β-1,4 glycosidic bond requires a multistep
                    synthetic sequence to obtain a regio- and stereoselective assembly of glycosidic bonds, crucial for
                    biological activity; (ii) the use of 2-acetamido-2-deoxyglycosyl donors, due to the formation of
                    1,2-<italic toggle="yes">O</italic>,<italic toggle="yes">N</italic>-oxazoline intermediates [<xref
                            rid="B14-pharmaceuticals-13-00392" ref-type="bibr">14</xref>,<xref
                            rid="B15-pharmaceuticals-13-00392" ref-type="bibr">15</xref>,<xref
                            rid="B16-pharmaceuticals-13-00392" ref-type="bibr">16</xref>,<xref
                            rid="B17-pharmaceuticals-13-00392" ref-type="bibr">17</xref>], and the use of corresponding
                    acceptors that are poor nucleophiles [<xref rid="B18-pharmaceuticals-13-00392" ref-type="bibr">
                        18</xref>].
                </p>
                <p>As mentioned above, the most demanding aspect in the synthesis of fragments of peptidoglycan is the
                    control of the stereoselectivity of the glycosidic bond. The pursuit of straightforward and
                    stereoselective methods for the assembly of PGN fragments remains an emerging research area. In this
                    review, after an overview of the biosynthesis of bacterial PGN, we highlight recent advances in the
                    synthesis of PGN fragments, focusing on the different strategies, including the selection of donors
                    and acceptors, reaction conditions, stereoselectivity of the glycosylation reaction, and peptide
                    coupling. Recently, chemoenzymatic approaches have been reported to solve problems associated with
                    the orthogonal and multistep processes usually required for PGN synthesis, which will also be
                    covered in this review.
                </p>
            </sec>
            <sec id="sec2-pharmaceuticals-13-00392">
                <title>2. Biosynthesis of the Bacterial Peptidoglycan</title>
                <p>PGN biosynthesis is conserved among Gram-positive and Gram-negative bacteria and occurs in three
                    different locations: (i) synthesis of uridine diphosphate (UDP)-activated PGN precursors in the
                    cytoplasm; (ii) synthesis of lipid-linked precursors at the inner leaflet of the cytoplasmatic
                    membrane; (iii) flipping to the outer leaflet of the cytoplasmatic membrane and incorporation of the
                    precursor into nascent PGN (<xref ref-type="fig" rid="pharmaceuticals-13-00392-f002">Figure 2</xref>).
                </p>
                <p>PGN biosynthesis starts with the conversion of fructose-6-phosphate into uridine diphosphate-GlcNAc
                    (UDP-GlcNAc) by GlmSMU enzymes [<xref rid="B19-pharmaceuticals-13-00392" ref-type="bibr">
                        19</xref>,<xref rid="B20-pharmaceuticals-13-00392" ref-type="bibr">20</xref>,<xref
                            rid="B21-pharmaceuticals-13-00392" ref-type="bibr">21</xref>,<xref
                            rid="B22-pharmaceuticals-13-00392" ref-type="bibr">22</xref>,<xref
                            rid="B23-pharmaceuticals-13-00392" ref-type="bibr">23</xref>,<xref
                            rid="B24-pharmaceuticals-13-00392" ref-type="bibr">24</xref>]. UDP-GlcNAc is converted to
                    uridine diphosphate-MurNAc (UDP-MurNAc) by MurAB enzymes [<xref rid="B25-pharmaceuticals-13-00392"
                                                                                    ref-type="bibr">25</xref>,<xref
                            rid="B26-pharmaceuticals-13-00392" ref-type="bibr">26</xref>,<xref
                            rid="B27-pharmaceuticals-13-00392" ref-type="bibr">27</xref>]. The <sc>d</sc>-amino acids
                    present in the PG are produced by the MurI and Alr racemases, which convert <sc>l</sc>-Glu to <sc>
                        d</sc>-Glu and L-Ala to
                    <sc>d</sc>
                    <italic toggle="yes">-</italic>Ala, respectively [<xref rid="B28-pharmaceuticals-13-00392"
                                                                            ref-type="bibr">28</xref>,<xref
                            rid="B29-pharmaceuticals-13-00392" ref-type="bibr">29</xref>,<xref
                            rid="B30-pharmaceuticals-13-00392" ref-type="bibr">30</xref>]. The amino acids L-Ala, D-Glu,
                    and L-Lys or DAP are added sequentially by the MurCDE enzymes, respectively, to the lactyl group of
                    UDP-MurNAc [<xref rid="B31-pharmaceuticals-13-00392" ref-type="bibr">31</xref>,<xref
                            rid="B32-pharmaceuticals-13-00392" ref-type="bibr">32</xref>,<xref
                            rid="B33-pharmaceuticals-13-00392" ref-type="bibr">33</xref>,<xref
                            rid="B34-pharmaceuticals-13-00392" ref-type="bibr">34</xref>]. The <sc>d</sc>-Ala-<sc>d</sc>-Ala
                    dipeptide present at the carboxyl end of the PGN stem peptide is first formed by Ddl ligases [<xref
                            rid="B35-pharmaceuticals-13-00392" ref-type="bibr">35</xref>] and then incorporated into the
                    UDP-MurNAc-tripeptide by MurF [<xref rid="B36-pharmaceuticals-13-00392" ref-type="bibr">
                        36</xref>,<xref rid="B37-pharmaceuticals-13-00392" ref-type="bibr">37</xref>], forming a
                    UDP-MurNAc-pentapeptide known as the Park nucleotide.
                </p>
                <p>The Park nucleotide is attached to undecaprenyl phosphate in the inner leaflet of the cytoplasmatic
                    membrane by MraY with the release of UDP. The resulting
                    MurNAc-(pentapeptide)-pyrophosphoryl-undecaprenol is known as lipid I [<xref
                            rid="B38-pharmaceuticals-13-00392" ref-type="bibr">38</xref>,<xref
                            rid="B39-pharmaceuticals-13-00392" ref-type="bibr">39</xref>,<xref
                            rid="B40-pharmaceuticals-13-00392" ref-type="bibr">40</xref>]. MurG converts lipid I into
                    lipid II (GlcNAc-<italic toggle="yes">β</italic>-(1,4)-MurNAc-(pentapeptide)-pyrophosphoryl-undecaprenol)
                    by adding the GlcNAc of a UDP-GlcNAc to lipid I with the release of UDP [<xref
                            rid="B41-pharmaceuticals-13-00392" ref-type="bibr">41</xref>,<xref
                            rid="B42-pharmaceuticals-13-00392" ref-type="bibr">42</xref>,<xref
                            rid="B43-pharmaceuticals-13-00392" ref-type="bibr">43</xref>].
                </p>
                <p>The resulting product, lipid II, is flipped from the inner leaflet to the outer leaflet of the
                    cytoplasmatic membrane. There is a debate regarding which enzyme is responsible for this step.
                    Although FtsW and MurJ are the two strongest candidates, the literature favors MurJ as the bona fide
                    flippase [<xref rid="B44-pharmaceuticals-13-00392" ref-type="bibr">44</xref>,<xref
                            rid="B45-pharmaceuticals-13-00392" ref-type="bibr">45</xref>,<xref
                            rid="B46-pharmaceuticals-13-00392" ref-type="bibr">46</xref>,<xref
                            rid="B47-pharmaceuticals-13-00392" ref-type="bibr">47</xref>,<xref
                            rid="B48-pharmaceuticals-13-00392" ref-type="bibr">48</xref>]. More recently, it has been
                    shown that certain enzymes in particular organisms may also exhibit lipid II flippase activity
                    [<xref rid="B49-pharmaceuticals-13-00392" ref-type="bibr">49</xref>].
                </p>
                <p>Precursor incorporation into nascent PG is achieved by reactions of transglycosylation (TG),
                    responsible for extending glycan chains, and reactions of transpeptidation (TP), responsible for
                    connecting adjacent glycan chains through their stem peptides. TG connects the lipid II GlcNac C4 to
                    the MurNAc C1 of the nascent PGN with the release of undecaprenyl pyrophosphate. After the
                    incorporation of the PGN precursor into the PGN macromolecule, undecaprenyl pyrophosphate is
                    subsequentially dephosphorylated, prior to its use in another cycle of glycan synthesis, leading to
                    the removal of one phosphate group, and is recycled for another cycle of Lipid precursor synthesis [<xref
                            rid="B50-pharmaceuticals-13-00392" ref-type="bibr">50</xref>,<xref
                            rid="B51-pharmaceuticals-13-00392" ref-type="bibr">51</xref>].
                </p>
            </sec>
            <sec id="sec3-pharmaceuticals-13-00392">
                <title>3. Synthetic Approaches towards PGN Fragments from Glucosamine I</title>
                <p>Currently, there is a pressing need for new approaches toward the chemical synthesis of PGN
                    fragments. This will permit in vitro studies of the biochemical activity of PBP enzymes [<xref
                            rid="B52-pharmaceuticals-13-00392" ref-type="bibr">52</xref>], which are important targets
                    for the development of new antibiotics. It will also ensure that samples of PGN, a telltale molecule
                    that flags an infected host to the presence of bacteria, are free of contaminants of bacterial
                    origin [<xref rid="B53-pharmaceuticals-13-00392" ref-type="bibr">53</xref>,<xref
                            rid="B54-pharmaceuticals-13-00392" ref-type="bibr">54</xref>].
                </p>
                <p>However, attempts to fully synthesize the PGN molecule in the laboratory in a way that is independent
                    of the use of components (substrates or enzymes) of bacterial origin have faced several
                    restrictions.
                </p>
                <p>The synthesis of NAG-containing oligosaccharides, such as the NAG-NAM disaccharide present in the PGN
                    molecule, poses considerable limitations associated with the enantioselective glycosylation of NAG
                    moieties with respect to both donor and acceptor units. Indeed, the glycosylation of complex
                    aglycones with glycosyl donors bearing 2-acetamido-2-deoxy functionality is usually impractical due
                    to the formation of a 1,2-<italic toggle="yes">O</italic>,<italic toggle="yes">N</italic>-oxazoline
                    intermediate during glycosylation. This is a stable intermediate, which drastically decreases the
                    rate and yield of the glycosylation step, especially when the chosen glycosyl acceptors have poor
                    nucleophilicity or are sterically hindered. Furthermore, the use of glycosyl acceptors bearing
                    2-acetamido-2-deoxy functionality is considered not to be a good strategy as the amide group in the
                    acceptor molecule can establish a hydrogen bond with the hydroxy group O-4, which decreases
                    nucleophilicity at this position. In order to avoid the formation of the stable 1,2-<italic
                            toggle="yes">O</italic>,<italic toggle="yes">N</italic> oxazoline intermediate, and improve
                    the formation of 1,2-<italic toggle="yes">trans</italic>-glycoside, different authors have used
                    various N-protecting groups in their attempt to synthesize PGN fragments. The N-protecting groups
                    that have been developed differ in their ability to direct the stereochemical outcome of the
                    glycosylation reactions and in their compatibility with diverse carbohydrate synthetic methods.
                </p>
                <p>In 2001, Fukase and co-workers reported the synthesis of PGN fragments [<xref
                        rid="B55-pharmaceuticals-13-00392" ref-type="bibr">55</xref>], in a follow-up of their previous
                    work [<xref rid="B56-pharmaceuticals-13-00392" ref-type="bibr">56</xref>]. The authors developed an
                    orthogonal synthesis that was able to create the building blocks required to achieve a PGN
                    fragment—the complex octasaccharide (NAG-NAM)<sub>4</sub> with two amino acid strands linked to
                    every NAM unit <bold>9</bold> (<xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch001">Scheme
                        1</xref>).
                </p>
                <p>The first step in the preparation of acceptor <bold>2</bold> consisted in the protection of the amine
                    group of <sc>d</sc>-glucosamine with the allyloxycarbonyl (Alloc) group by treatment of glucosamine
                    with AllocCl in the presence of NaHCO<sub>3</sub> as a base. Next, the anomeric position was
                    protected with the <italic toggle="yes">O</italic>-Allyl group, by reaction with allyl alcohol under
                    acidic conditions using DOWEX as a proton exchange resin at high temperature. The O-4 and O-6
                    positions were regioselectively protected via acetylidene formation by treatment with benzaldehyde
                    dimethyl acetal catalyzed by <italic toggle="yes">p</italic>-TsOH in 57% yield. This strategy is a
                    well-known procedure for the regioselective protection of both the O-6 and O-4 positions.
                </p>
                <p>For the introduction of the lactyl moiety at the O-3 position, the authors used
                    trifluoromethanesulfonyl-<sc>l</sc>-(<italic toggle="yes">S</italic>)-2-propionic acid benzyl ester
                    after hydroxy group deprotonation with NaH, and the product was isolated in 98% yield. The
                    N-protection achieved with the introduction of the Alloc group is crucial to install the lactyl
                    moiety at the O-3 position. However, the presence of this group will not permit the correct β-1,4
                    selectivity during the glycosylation reaction [<xref rid="B14-pharmaceuticals-13-00392"
                                                                         ref-type="bibr">14</xref>]. In order to obtain
                    β-1,4 linkage, the authors replaced the Alloc group with the trichloroethoxycarbonyl (Troc) group.
                    The Alloc group was first removed via treatment with a complex of Pd(PPh<sub>3</sub>)<sub>4</sub> assisted
                    by AcOH. The palladium complex coordinates with the double bond from the Alloc group, followed by
                    hydrolysis with AcOH. Then TrocCl was added to provide the N-Troc product in 58% yield. The use of
                    Troc as an N-protecting group at the acceptor moiety allowed for the simplified removal of the
                    protecting groups in a later stage of the synthesis. Consequently, selective ring opening was
                    performed to make the O-4 position free in preparation for the glycosylation reaction, using Me<sub>
                        3</sub>N·BH<sub>3</sub> to reduce the benzylic position, leaving the O-4 position free and
                    providing the acceptor <bold>2</bold> in 87% yield.
                </p>
                <p>The donor <bold>4</bold> was prepared via intermediate <bold>3</bold>, which was obtained from <sc>
                    d</sc>-glucosamine using a similar approach as that described for the acceptor, consisting of:
                    N-protection with TrocCl, protection of the anomeric position with the <italic toggle="yes">
                        O</italic>-Allyl group, and formation of the acetylidene. To prepare the donor unit, the authors
                    protected the O-3 position with the Bn group, using BnBr, through a S<sub>N</sub>2 reaction
                    catalyzed by AgO and obtained the product in 87% yield. The next step consisted in the conversion of
                    the <italic toggle="yes">O</italic>-Allyl group into a trichloroacetimidate group. Thus, the authors
                    removed the <italic toggle="yes">O</italic>-Allyl group with an Ir complex to isomerize the double
                    bond, promoting the H<sub>2</sub>O nucleophilic attack at the anomeric position. The next step
                    consisted in the treatment of the anomeric position of the donor with CCl<sub>3</sub>CN and Cs<sub>
                        2</sub>CO<sub>3</sub> as a base, leading to the product <bold>4</bold> in a quantitative yield.
                </p>
                <p>The next step consisted in the glycosylation reaction using <bold>2</bold> as an acceptor and <bold>
                    4
                </bold> as a donor. Since the trichloroacetimidate group is an excellent leaving group, TMSOTf was used
                    in a catalytic amount, along with molecular sieves, to promote the glycosylation reaction, providing <bold>
                        5
                    </bold> in 88% yield.
                </p>
                <p>Once the disaccharide <bold>5</bold> was obtained, the same rationale was used to produce the
                    tetrasaccharide <bold>8</bold>, including the selective ring opening to provide the acceptor <bold>
                        6</bold>, and replacement of the O-Allyl group with the trichloroacetimidate group to provide
                    the donor <bold>7</bold>. The synthesis of the octasaccharide followed a similar approach via
                    preparation of both acceptor and donor tetrasaccharides <bold>8a</bold> and <bold>8c</bold>,
                    respectively. After obtaining the octasaccharide, the authors attached the dipeptide via solid-phase
                    peptide synthesis. The remaining benzyl groups were removed by a hydrogenation reaction.
                </p>
                <p>Overall, the authors carried out 25 steps to achieve compound <bold>9</bold>. This study [<xref
                        rid="B55-pharmaceuticals-13-00392" ref-type="bibr">55</xref>] was a milestone in the synthesis
                    of PGN fragments. To perform this synthetic plan, the authors had to carefully choose all the
                    protecting groups, in particular the N-protecting group and the protection of the anomeric position.
                    As the <italic toggle="yes">N</italic>-Alloc group, a well-known group that allows many chemical
                    modifications, does not favor β-1,4 glycosidic bond formation in glycosylation reactions, the
                    authors installed the Troc group which is a β-1,4 director.
                </p>
                <p>In 2001, Wang and co-workers reported the orthogonal synthesis of the Lipid II unit <bold>16</bold>, <xref
                        ref-type="scheme" rid="pharmaceuticals-13-00392-sch002">Scheme 2
                </xref> [<xref rid="B57-pharmaceuticals-13-00392" ref-type="bibr">57</xref>]. The authors aimed to
                    develop an appropriate assay system for the observation of catalytic transformations involving
                    PBP1b, a penicillin binding protein that in <italic toggle="yes">E. coli</italic> is involved in the
                    transglycosylation and transeptidation of PGN precursors, since this area of study had been limited
                    by the available amounts of Lipid II.
                </p>
                <p>The synthesis started with the preparation of the acceptor unit <bold>11</bold> from the commercially
                    available MurNAc derivative <bold>10</bold>. The first step was to install the L-alanine unit to
                    avoid the unwanted cyclization of compound <bold>11</bold>, observed when the lactate was protected
                    as an ester. This reaction was followed by removal of the arylidene group and acetylation of the
                    free 6-hydroxy group, affording the acceptor <bold>11</bold> with a 57% yield after three steps.
                </p>
                <p>As a donor, the authors used the commercially available donor <bold>12</bold>, a glycosyl bromide
                    possessing the <italic toggle="yes">N</italic>-phthalimide group. The glycosylation was carried in
                    the presence of AgOTf and, with the participation of the <italic toggle="yes">N</italic>-phathalimido
                    group in <bold>13</bold> that oriented the attack on the β face, the desired compound <bold>13
                    </bold> was isolated in 60% yield. Next, the phtaloyl group in <bold>13</bold> was removed with
                    concomitant <italic toggle="yes">N</italic>-acetylation using an amino-modified resin and acetic
                    anhydride. Compound <bold>13</bold> was then converted to the desired phosphate <bold>14</bold> via
                    consecutive anomeric deprotection and phosphorylation. Thus, hydrogenation of the benzyl group
                    in <bold>13</bold>, using the classical conditions 10% Pd/C afforded the free OH. Phosphorylation
                    was performed in a one-pot, two-step procedure, consisting of the initial formation of the
                    phosphite, followed by in situ oxidation with m-CPBA. The authors used (BnO)<sub>2</sub>PN(<italic
                            toggle="yes">i</italic>-Pr)<sub>2</sub>, followed by <italic toggle="yes">m</italic>-CPBA
                    oxidation, to provide <bold>14</bold> with 27% yield after three steps. Next, the silyl group from
                    alanine was removed by means of treatment with TBAF, followed by pentapeptide coupling using the
                    standard conditions reported by the authors. The final steps relied on the undecaprenyl unit
                    coupling and removal of the protecting groups. The benzyl groups from <bold>14</bold> were removed
                    by hydrogenation, followed by coupling with undecaprenyl phosphate using CDI as a coupling agent to
                    obtain <bold>15</bold>. After removal of the silyl group using TBAF and removal of the acetyl groups
                    under Zemplén’s conditions the Lipid II unit <bold>16</bold> was obtained, consisting of the first
                    synthesis with 12 steps.
                </p>
                <p>Blaszczak and co-workers reported, in 2001, the synthesis of the compound <bold>20</bold> [<xref
                        rid="B58-pharmaceuticals-13-00392" ref-type="bibr">58</xref>] and then in 2002 reported the
                    final steps to afford the Lipid II unit <bold>16</bold> (<xref ref-type="scheme"
                                                                                   rid="pharmaceuticals-13-00392-sch003">
                        Scheme 3</xref>) [<xref rid="B59-pharmaceuticals-13-00392" ref-type="bibr">59</xref>].
                </p>
                <p>The synthesis of <bold>16</bold> started with the coupling of alanine to the commercially available
                    monosaccharide <bold>10</bold> in 95% yield, followed by the reductive opening of arylidene using Et<sub>
                        3</sub>SiH, giving the acceptor <bold>17</bold> in 61% yield. The glycosylation reaction with of <bold>
                        17
                    </bold> with the donor glycosyl bromide <bold>18</bold>, containing the NHTroc group, was carried
                    out in the presence of AgOTf as a catalyst, in 84% yield. Next, the <italic toggle="yes">O</italic>-6
                    benzyl group was removed, followed by acetylation of the positions O6 and N2 using ZnCl<sub>2</sub> and
                    Ac<sub>2</sub>O. The N-Troc group was removed using Zn dust in a multistep reaction, yielding <bold>
                        19
                    </bold> in 67% yield. The authors hydrogenated the OBn group, followed by insertion of the phophoryl
                    group, affording <bold>20</bold> in 73% after two steps. The tetrapeptide was coupled using EDCI,
                    followed by hydrogenation of the Bn groups, affording <bold>21</bold> in 41% yield (two steps). The
                    final steps consisted in the coupling of the undecaprenyl moiety using undecaprenyl phosphate and
                    CDI, followed by the removal of the acetyl groups under Zemplén’s conditions, to afford Lipid II
                    unit <bold>16</bold>. This synthesis was carried out in 10 steps.
                </p>
                <p>Other groups of researchers have reported alternative strategies to produce molecules that could be
                    used in the synthesis of PGN. In 2002, the Boons group developed the synthesis of a high value
                    disaccharide which can be converted into the intermediates <bold>26</bold> and <bold>27</bold>,
                    precursors of the NAM-NAG and NAG-NAM disaccharides, respectively (<xref ref-type="scheme"
                                                                                             rid="pharmaceuticals-13-00392-sch004">
                        Scheme 4</xref>) [<xref rid="B60-pharmaceuticals-13-00392" ref-type="bibr">60</xref>].
                </p>
                <p>In their report, the authors started the synthesis of PGN fragments with compound <bold>22,</bold> which
                    possesses the phthalimide (Phth) group as an N-protecting group, a 4,6-<italic toggle="yes">O
                    </italic> arylidene ring, and an SEt group at the anomeric position. The O-3 position of <bold>22
                    </bold> was protected with TBDMSOTf, affording <bold>23</bold> as the donor unit in 96% yield.
                </p>
                <p>Concerning the preparation of acceptor <bold>24</bold>, the synthesis started with the protection of
                    the O-3 position of <bold>22</bold> with the PMB group, using PMBCl and NaH in 84% yield. The next
                    step consisted in the opening of the arylidene ring to make the O-4 position free. This was achieved
                    using Me<sub>3</sub>N·BH<sub>3</sub> as a reducing agent, and the desired product was obtained in
                    72% yield. Next, the authors replaced the SEt group with 3-azido-propanol. Subsequent treatment with
                    NIs oxidized SEt to S(O)Et, and this intermediate was attacked by 3-azido-propanol to afford <bold>
                        24
                    </bold> in 67% yield. Interestingly, the authors highlighted that due to the low reactivity of O-4,
                    self-condensation was not observed.
                </p>
                <p>Having both acceptor <bold>24</bold> and donor <bold>23</bold> in hand, the next step consisted in
                    the glycosylation reaction. The activation of the anomeric group with NIS promoted the nucleophilic
                    attack of the hydroxyl group of the acceptor <bold>24</bold> to the donor <bold>23</bold>, affording
                    the corresponding disaccharide in 62% yield. Once the synthesis of the disaccharide was obtained,
                    the N-Phth group was removed by treatment with hydrazine at reflux, followed by an acetylation step,
                    giving the N-acetylated product <bold>25</bold> in 70% yield.
                </p>
                <p>The intermediate <bold>25</bold> was used to prepare both the NAM-NAG precursor <bold>26</bold> and
                    the NAG-NAM precursor <bold>27</bold>. To produce <bold>26</bold> the authors removed the TBDMS
                    group using tetrabutylamoniun fluoride (TBAF) in 75% yield, followed by the introduction of the
                    lactyl moiety. The authors used (<italic toggle="yes">S</italic>)-2-chloropropionic acid after
                    deprotonation of O-3 with NaH, affording the corresponding product in 76% yield. To obtain <bold>
                        27
                    </bold> the authors removed the PMB group using DDQ in 79% yield, followed by the introduction of
                    the lactyl moiety, using the same procedure used for <bold>26</bold>, in 66% yield.
                </p>
                <p>In their synthetic strategy, the authors selected the Phth group as the N-protecting group, since it
                    blocks the nitrogen atom and is only removed by reduction with hydrazine. In addition, a
                    thioglycoside was used as a glycosyl donor due to its versatility and stability and for being a good
                    leaving group when activated with NIS.
                </p>
                <p>Overall, the authors synthesized two disaccharides, which are similar to components of bacterial PGN,
                    in eight steps. Their strategy consisted in first synthesizing the disaccharide unit and afterwards
                    performing the insertion of the lactate moiety. The lactonization of muramic acid derivatives
                    possessing a free O-4 position is a major obstacle. As mentioned above, Blaszczak and co-workers
                    [<xref rid="B58-pharmaceuticals-13-00392" ref-type="bibr">58</xref>,<xref
                            rid="B59-pharmaceuticals-13-00392" ref-type="bibr">59</xref>] addressed this problem by
                    installing the <sc>l</sc>-alanine in the glycosyl acceptor for the synthesis of a disaccharide. The
                    route developed by the Boons group addressed this challenge by synthesizing a disaccharide and
                    thereafter incorporating the lactate unit; consequently, one disaccharide can be used for the
                    synthesis of both PGN units (MurNAc-GlcNAc and GlcNAc-MurNAc).
                </p>
                <p>The N-Troc group of the glycosyl donor is known to be very reactive [<xref
                        rid="B18-pharmaceuticals-13-00392" ref-type="bibr">18</xref>], directing glycosylation
                    exclusively to produce 1,2-<italic toggle="yes">trans</italic> linked glycosides via neighboring
                    group participation. The authors found that glycosyl donors that were protected with phthalimido
                    groups led to high-yielding glycosylations. This N-protecting group is compatible with strong basic
                    conditions used for the incorporation of the lactate moiety, whereas the Troc group would not
                    survive these conditions.
                </p>
                <p>Soon after, in 2004, Mobashery and co-workers reported the synthesis of another PGN fragment—a
                    tetrasaccharide, with two pentapeptides attached to the NAM units, <bold>33</bold> (<xref
                            ref-type="scheme" rid="pharmaceuticals-13-00392-sch005">Scheme 5</xref>) [<xref
                            rid="B61-pharmaceuticals-13-00392" ref-type="bibr">61</xref>].
                </p>
                <p>These authors started their synthesis by preparing both <bold>28</bold> and <bold>29</bold> from
                    glucosamine via orthogonal synthesis. This began with protecting the amino group of glucosamine with
                    the dimethyl maleimide (DMM) group, using 2,3-dimethylmaleic anhydride followed by acetylation of
                    the hydroxy groups, affording the corresponding product in 55% yield after two steps. This <italic
                            toggle="yes">N</italic>-DMM glucosamine intermediate was the precursor for both the donor <bold>
                        28
                    </bold> and the acceptor <bold>29</bold>.
                </p>
                <p>To prepare <bold>28</bold> the authors selectively deprotected the anomeric acetyl group using
                    hydrazine acetate to give a free OH group at the anomeric position in 68% yield. Then, at this
                    position, the trichloroacetimidate group was introduced by treatment with CCl<sub>3</sub>CN and DBU
                    as a base, providing the donor <bold>28</bold> in 85% yield.
                </p>
                <p>Concerning the preparation of acceptor <bold>29</bold>, the authors selectively removed the anomeric
                    acetyl group from peracetylated N-DMM glucosamine, using hydrazine acetate (68% yield), followed by
                    silylation of the anomeric hydroxyl group using TBDMSCl and imidazole to afford the silylated
                    product in 78% yield. Next, the remaining acetyl groups were removed using NaOMe in methanol and the
                    product was obtained in 73% yield. The benzylation of the O-3 and O-6 was performed using Bu<sub>
                        2</sub>SnO and BnBr, and the acceptor <bold>29</bold> was isolated in 73% yield.
                </p>
                <p>Having both donor <bold>28</bold> and acceptor <bold>29</bold> in hand, the glycosylation reaction
                    was performed. This step was carried using TfOH as a promotor, producing the desired disaccharide in
                    75% yield. Three additional steps were needed to produce disaccharide <bold>30</bold>. In the first
                    step there was the removal of the acetyl group using NaOMe that was quenched by the use of a proton
                    exchange resin (Amberlite IR-120). In the second step, the authors executed the subsequent reaction
                    with benzaldehyde dimethylacetal, leading to the formation of 4,6-<italic toggle="yes">O</italic> arylidene,
                    and then O-6 and O-3 benzylation, (60%, in the two steps). The last step consisted in the
                    acetylation of the remaining free O-3 position with acetic anhydride, affording <bold>30</bold> in
                    85% yield.
                </p>
                <p>Glycan chain elongation using <bold>30</bold> as a substrate was then required. In order to achieve
                    this, the TBDMS group was removed with TBAF in 75% yield. The authors observed that for long
                    reaction times, the yield decreased due to hydrolysis of the acetyl group. Then, the
                    trichloroacetimidate group was introduced, followed by a glycosylation reaction with an acceptor A (<xref
                            ref-type="scheme" rid="pharmaceuticals-13-00392-sch005">Scheme 5</xref>) possessing both O-6
                    benzylated and O-3 acetylated and an OMe group at the anomeric position, affording the corresponding
                    trisaccharide in 55%. Next, the selective opening of the 4,6-<italic toggle="yes">O</italic>-arylidene
                    ring with Me<sub>3</sub>N·BH<sub>3</sub> gave the corresponding trisaccharide with the free O-4
                    position in 62% yield.
                </p>
                <p>The next glycosylation reaction was performed using this trisaccharide as an acceptor and the
                    monosaccharide B as a donor (<xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch005">Scheme
                        5</xref>), possessing a 4,6-<italic toggle="yes">O</italic>-arylidene ring, O-3 protected with a
                    benzyl group, and the trichloroacetimidate group at the anomeric position. This glycosylation
                    reaction was once again catalyzed by TfOH, affording <bold>31</bold> in 68%
                </p>
                <p>At this stage the DMM group was no longer needed, and it was removed by treatment of <bold>31</bold> with
                    NaOH in dioxane/water (4:1), quenched with HCl until reaching pH 3, followed by a reaction with
                    acetic anhydride. The corresponding <italic toggle="yes">N</italic>-acetylated product was isolated
                    in 48% yield. To introduce the lactyl moieties, the authors removed the <italic toggle="yes">
                        O</italic>-acetyl groups using NaOMe with 74% yield, followed by treatment with (<italic
                            toggle="yes">S</italic>)-2-chloropropionic acid (after deprotonation with NaH), and <bold>
                        32
                    </bold> was obtained in 46% yield.
                </p>
                <p>The final steps involved the coupling of the tetrasaccharide with a synthesized pentapeptide
                    (prepared as a CF<sub>3</sub>CO<sub>2</sub>H salt) in a 41% yield, and removal of the benzyl groups
                    by hydrogenation, affording <bold>33</bold> in 76% yield.
                </p>
                <p>The authors reported the synthesis of the tetrasaccharide <bold>33</bold> in 18 steps. Their strategy
                    relied on the preparation of a disaccharide moiety possessing two O-3 positions that were
                    differently protected (OAc and OBn), which once glycosylated with a donor and acceptor with the same
                    O-3 protective groups led to a tetrasaccharide, which allowed alternated installations of the lactyl
                    moiety. This was the first report on the synthesis of a tetrasaccharide with the pentapeptide linked
                    to the two <italic toggle="yes">O</italic>-3 lactyl groups.
                </p>
                <p>Several PGN fragments, mono-, di-, tetra-, and octasaccharides with the pentapeptide assembled were
                    synthesized by the Fukase group in order to understand how the innate immune response was triggered
                    [<xref rid="B62-pharmaceuticals-13-00392" ref-type="bibr">62</xref>]. The synthesis of these PGN
                    fragments relied on a previous report from the same authors [<xref
                            rid="B55-pharmaceuticals-13-00392" ref-type="bibr">55</xref>], using Troc as the protecting
                    group for the amine moiety and the trichloroacetimidate group at the anomeric position. With these
                    studies, the authors determined that the minimal recognition pattern for hPGRP-L, a human protein
                    capable of binding bacterial PGN fragments, was the NAM unit linked to three amino acids.
                    Furthermore, these authors also used the assembled synthetic PGN fragment to discover that the NAM
                    unit linked to two amino acids (MDP) was recognized by NOD2, a protein that is involved in the
                    activation of an innate immune response in murine cells.
                </p>
                <p>In 2007 Walker and co-workers reported the synthesis of a PGN precursor that may be used by bacterial
                    enzymes that are involved in the assembly of the PGN macromolecule—the heptaprenyl-lipid IV <bold>
                        43b</bold>, which consists of a tetrasaccharide (NAG-NAM)<sub>4</sub> linked to a diphospholipid
                    at the anomeric position (<xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch006">Scheme
                        6</xref>) [<xref rid="B63-pharmaceuticals-13-00392" ref-type="bibr">63</xref>].
                </p>
                <p>The strategy proposed by these authors relied on the preparation of a tetrasaccharide possessing
                    alternated free hydroxyl groups at the O-3 position that could then be used to install the lactyl
                    unit and the posterior attachment of the peptide chain, while the lipid moiety was introduced using
                    a thioglycoside as donor.
                </p>
                <p>The authors started the synthesis with the common starting material <bold>34</bold> that was
                    converted into monosaccharides <bold>35</bold>, <bold>36</bold>, and <bold>37</bold>—building blocks
                    required to assemble the desired tetrasaccharide. Glucosamine derivative <bold>34</bold> was
                    converted into <bold>35</bold> in three steps. In the first step, they used an O-6 and O-3
                    benzylation using Bu<sub>2</sub>SnO and BnBr in 51% yield. The second step involved O-4 silylation
                    by means of treatment with TBSOTf and lutidine in 91% yield. In the third and final step, the
                    authors performed the oxidation of the thioglycoside, with <italic toggle="yes">m</italic>CPBA
                    affording <bold>35</bold> in 93% yield.
                </p>
                <p>The production of <bold>36</bold> and <bold>37</bold> did not require so many steps. Treatment of <bold>
                    34
                </bold> with (Bu<sub>3</sub>Sn)<sub>2</sub>O, followed by the addition of BnBr/TBAI (O-6 benzylation)
                    led to <bold>36</bold> in 75% yield. The donor <bold>37</bold> was obtained by oxidation of <bold>
                        24
                    </bold> with <italic toggle="yes">m</italic>CPBA.
                </p>
                <p>Glycosylation of <bold>35</bold> with <bold>36</bold> mediated by Tf<sub>2</sub>O followed by
                    oxidation with <italic toggle="yes">m</italic>CPBA led to formation of the disaccharide <bold>38a
                    </bold> in 86% yield. N-protection with the tetrachlorophthalimide (TCP) group hindered the O-3
                    glycosylation reaction, which was expected due to the presence of the free hydroxyl group at O-3,
                    and permitted the formation of a β-1,4 glyosidic bond. The disaccharide <bold>38b</bold> was
                    obtained in 58% yield via the inverted addition of <bold>37</bold> to the acceptor <bold>35</bold>.
                </p>
                <p>The glycosylation of the two disaccharides (<bold>38a</bold> and <bold>38b</bold>) afforded the
                    desired tetrasaccharide in 77% yield. Next the N-TCP group was replaced by the N-acetyl group via
                    treatment of the tetrasaccharide with hydrazine and subsequent N-acetylation with acetic anhydride
                    in 75% yield (two steps). The generated tetrasaccharide possessed alternated free O-3 positions,
                    which were ready to receive the lactyl moiety. The authors introduced the lactyl moiety
                    using <italic toggle="yes">S</italic>-(<italic toggle="yes">–</italic>)-2-bromo-propionic acid,
                    followed by an <italic toggle="yes">O</italic>-alkylation step, affording <bold>39</bold> in 70%
                    yield.
                </p>
                <p>In order to install the phosphonate moiety at the anomeric position, which yielded compound <bold>
                    40</bold>, the compound <bold>39</bold> was subjected to a sequence of five synthetic steps,
                    involving the oxidation of SPh with NIS in 75% yield, treatment with (<italic toggle="yes">
                        i</italic>-Pr)<sub>2</sub>NP(OBn)<sub>2</sub> and subsequent oxidation with <italic
                            toggle="yes">m</italic>CPBA in 84% yield (two steps), TBS group removal, and hydrolysis of
                    the ester groups.
                </p>
                <p>The coupling of the silyl-protected pentapeptide <bold>41</bold>, which had been previously
                    synthesized using Fmoc chemistry, with tetrasaccharide <bold>40</bold> was performed using standard
                    peptide coupling conditions. This approach led to tetrasaccharide <bold>42</bold>, which was
                    obtained after global hydrogenolysis in 44% yield.
                </p>
                <p>Next, the coupling of the heptaprenyl phosphate [<xref rid="B64-pharmaceuticals-13-00392"
                                                                          ref-type="bibr">64</xref>] to the anomeric
                    phosphate present in compound <bold>42</bold> was performed with 1,1′-carbonyl diimidazole in 50%
                    yield. The final steps consisted in the removal of the silyl groups, which resulted in the
                    heptaprenyl—Lipid IV <bold>43a</bold>. In order to perform certain enzymatic assays, the authors
                    further converted <bold>43a</bold> into <bold>43b</bold> by treatment with [<xref
                            rid="B14-pharmaceuticals-13-00392" ref-type="bibr">14</xref>] C-acetic anhydride.
                </p>
                <p>In this report the authors established an orthogonal synthetic plan based on the use of a building
                    block possessing the amino group protected with tetrachlorophthalimide (TCP) and the thiophenol
                    group at the anomeric position. The authors then used the synthesized PGN building blocks, together
                    with a bacterial enzyme, PBP1a, a peptidoglycan glycosyltransferase from <italic toggle="yes">E.
                        coli</italic>, to elongate the PGN strand. They successfully mimicked the natural process and
                    were able to convert the synthetic tetrasaccharide into octasaccharide in 51% yield.
                </p>
                <p>More recently, Fukase and co-workers reported the first synthesis of cross-linked PGN fragments that
                    are frequently found at the cell wall of <italic toggle="yes">Streptococcus pneumoniae</italic> bacteria
                    [<xref rid="B65-pharmaceuticals-13-00392" ref-type="bibr">65</xref>]. The authors were able to use
                    the disaccharide <bold>44</bold> from previous reports [<xref rid="B55-pharmaceuticals-13-00392"
                                                                                  ref-type="bibr">55</xref>,<xref
                            rid="B66-pharmaceuticals-13-00392" ref-type="bibr">66</xref>] as a key intermediate in order
                    to cross-link the peptide chains (<xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch007">
                        Scheme 7</xref>).
                </p>
                <p>The ester group from disaccharide <bold>44</bold> was hydrolyzed to the carboxylic acid and the Boc
                    group from the peptide substrate was removed. The peptide was then coupled to the disaccharide using
                    the standard procedure with HATU, affording <bold>45</bold> in 75% yield. The authors further
                    attempted to introduce two glycan chains to the two <sc>l</sc>-Ala residues of the linked structure.
                    However, the desired compounds were not obtained due to insufficient reactivity of the amino groups.
                </p>
                <p>Next, the benzylidene acetal was removed after treatment with 10% TFA. The authors reported
                    difficulties associated with the removal of the Fmoc group from the peptide chain due to low
                    solubility, but it was accomplished after treatment with 20% piperidine.
                </p>
                <p>The coupling of the second disaccharide moiety was carried out using the same conditions as before,
                    affording the corresponding product in 26–42% yield, depending on the lysine protecting group (Z or
                    Ac). Final hydrogenation removed all the benzyl groups and <bold>46</bold> was afforded in
                    quantitative yield.
                </p>
                <p>The authors investigated the biological activity of all the synthetic PGN fragments and found that
                    the cross-linked PGN fragment is not the major ligand of human NOD2.
                </p>
                <p>This synthetic route developed by Fukase and coworkers established a plan that allows access to
                    longer PGN structures, which might be useful for the investigation in innate immunostimulation of
                    PGN. Indeed, on the basis of this study and PGN fragments, other biological activities can be
                    investigated, as well as the determination of the structural requirements for other types of PGN
                    recognition molecules including peptidoglycan recognition proteins (PGRPs) and PGN-recognizing
                    lectins.
                </p>
                <p>Some years later, the Fukase group reported the synthesis of several disaccharide and tetrasaccharide
                    fragments, which were used to investigate their ability to stimulate human Nod2 (hNod2)-dependent
                    responses [<xref rid="B67-pharmaceuticals-13-00392" ref-type="bibr">67</xref>]. Nod2 can recognize
                    specific fragments of the bacterial cell-wall PGN (the minimum ligand is the muramyl dipeptide
                    (MDP)). Enzymatic digestion of PGN appears to be important for Nod2 recognition. PGN is degraded by
                    muramidase or glucosamidase, producing two types of glycan sequence—glycans containing NAGβ(1-4)NAM
                    or NAMβ(1-4)NAG. Thus, the authors prepared fragments of diverse composition to understand whether
                    the sequence of these PGN fragments could affect an immune response that was dependent on the innate
                    immune receptor Nod2 (<xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch008">Scheme 8</xref>).
                </p>
                <p>In their work, the authors applied previously reported synthetic studies [<xref
                        rid="B68-pharmaceuticals-13-00392" ref-type="bibr">68</xref>,<xref
                        rid="B69-pharmaceuticals-13-00392" ref-type="bibr">69</xref>]. Compound <bold>49</bold> was
                    synthesized in 84% yield via the glycosylation reaction of <bold>47</bold> with <bold>48</bold> mediated
                    by TMSOTf as a catalytic promotor. Disaccharide <bold>49</bold> was converted into the acceptor <bold>
                        50
                    </bold> and donor <bold>51</bold>, to assemble the desired tetrasaccharide <bold>52</bold>.
                    Preparation of acceptor <bold>50</bold> involved the regioselective opening of the arylidene ring to
                    free the O-4 position under standard reductive conditions using Me<sub>3</sub>N·BH<sub>3</sub> in
                    ACN for 1 h, affording <bold>50</bold> in 83% yield. The donor <bold>51</bold> was prepared in three
                    steps from <bold>49</bold>, involving different reactions: (1) the isomerization of the allyl double
                    bond, using an Ir complex; (2) the subsequent hydrolysis assisted by iodine, in 81% yield for these
                    two steps; and (3) the final installation of the trichloroacetimidate group at the anomeric position
                    in a quantitative yield.
                </p>
                <p>Tetrasaccharide <bold>52</bold> was obtained after glycosylation using TMSOTf as a promotor in 16%
                    yield. In their work, the authors also described the use of glycosyl <italic toggle="yes">N</italic>-phenyltrifluoroacetoamidate
                    as a donor, due to its high reactivity and better stability when compared to the corresponding
                    trichloroacetimidates. The formation of byproducts such as the <italic toggle="yes">N</italic>-glycosyl
                    trifluoroacetamides is suppressed, since the <italic toggle="yes">N</italic>-phenyl group of the
                    eliminated <italic toggle="yes">N</italic>-phenyltrifluoroacetamide prevents the undesirable attack
                    of the amide on the cationic intermediates. The authors also performed the glycosylation using
                    a <italic toggle="yes">N</italic>-phenyltrifluoroacetimidate donor by increasing the equivalent
                    amount of acceptor <bold>50</bold> (donor/acceptor ratio 1:1.5), with an improved yield of 61%, and
                    preserving the selectivity.
                </p>
                <p>Next, the Troc group from tetrasaccharide <bold>52</bold> was removed using a Zn/Cu in AcOH for 3 h,
                    followed by an N-acetylation reaction (acetic anhydride in pyridine for 2 h). The saponification of
                    the ethyl esters with LiOH afforded the corresponding product in a quantitative yield.
                </p>
                <p>The following steps involved the condensation of the tetrasaccharide with a library of peptides with
                    a composition found in the bacterial PGN (i.e., di-, tri-, tetra-, and pentapeptides). Thus,
                    different protocols were used depending on the peptide chain required. After the final
                    hydrogenation, a library of PGN fragments <bold>54</bold> was obtained in yields ranging from 38% to
                    98%.
                </p>
                <p>Fukase and co-workers demonstrated that hNod2 recognition is dependent on the glycan sequence. The
                    authors compared the activities of glycans with the same peptide moieties, and showed that
                    (MurNAcβ(1-4)GlcNAc)<sub>2</sub>-containing structures exhibited stronger activity than those
                    containing (GlcNAcβ(1-4)MurNAc)<sub>2</sub>. These results indicate that differences in the
                    enzymatic degradation process may affect the host’s immunomodulation process.
                </p>
                <p>More recently, our group reported the synthesis of a NAGβ-(1-4)-NAM moiety <bold>61</bold>, which is
                    crucial for the preparation of synthetic components of a bacterial peptidoglycan (<xref
                            ref-type="scheme" rid="pharmaceuticals-13-00392-sch009">Scheme 9</xref>) [<xref
                            rid="B70-pharmaceuticals-13-00392" ref-type="bibr">70</xref>].
                </p>
                <p>In 2016, Fukase and co-workers reported a chemoenzymatic approach to the large-scale synthesis of
                    a <italic toggle="yes">meso</italic>-DAP type PGN from <italic toggle="yes">Mycobacterium</italic> [<xref
                            rid="B71-pharmaceuticals-13-00392" ref-type="bibr">71</xref>]. Since <italic toggle="yes">
                        meso</italic>-DAP has been reported to be the most potent activator of Nod2, there was a need to
                    develop a large-scale synthesis protocol. The use of <sc>l</sc>-aminocyclase and <sc>d</sc>-aminocyclase
                    was a key factor in the production of <italic toggle="yes">meso</italic>-DAP on a large scale in
                    order to proceed with the biological studies.
                </p>
                <p>The proposed route involved the preparation of both donor <bold>56</bold> and acceptor <bold>58
                </bold> from <italic toggle="yes">N</italic>-Troc glucosamine <bold>55</bold> and <italic toggle="yes">
                    N</italic>-Alloc glucosamine <bold>57</bold>, respectively. The synthetic sequence relied on
                    standard orthogonal protection of the hydroxyl groups, involving four steps for the preparation
                    of <bold>56</bold>: (i) the formation of the O-4,6 arylidene; (ii) an O-3 and O-1 acetylation, via
                    treatment with benzaldehyde dimethyl acetal and ZnCl<sub>2</sub>, the crude dissolved in pyridine
                    and acetic anhydride, in 78% yield (two steps); (iii) the selective removal of the anomeric acetyl
                    group using morpholine, in 87% yield; and (iv) the final establishment of the desired glycosyl
                    trichloroacetamidate using CCl<sub>3</sub>CN/Cs<sub>2</sub>CO<sub>3</sub>, affording <bold>56</bold> in
                    74% yield, which was used in the glycosylation reaction without further purification.
                </p>
                <p>The acceptor <bold>58</bold> was prepared in five steps, involving the following reactions: (i) the
                    benzylation of the anomeric position using BnOH and AcCl in 61% yield; (ii) the formation of the
                    4,6-O arylidene, in 72% yield; (iii) the introduction of the lactyl moiety at O-3 using
                    trifluoromethanesulfonyl-<sc>l</sc>-(<italic toggle="yes">S</italic>)-2-propionic acid ethyl ester,
                    in 68% yield; (iv) the removal of the Alloc group by treatment with Pd(PPh<sub>3</sub>)<sub>4.</sub> followed
                    by in situ N-protection with TrocCl, affording the corresponding product in 82% yield; and (v) a
                    final selective arylidene ring opening using the classical procedure with Me<sub>3</sub>N·BH<sub>
                        3</sub>, affording <bold>58</bold> in 72% yield.
                </p>
                <p>The glycosylation reaction was carried using TMSOTf as a promoter, giving the product <bold>59</bold> with
                    the desired β-1,4 selectivity, in 52% yield. The exchange of both trichloroethyl carbamate groups by
                    the natural N-acetyl group was performed by addition of Zn–Cu in AcOH/Ac<sub>2</sub>O/THF, followed
                    by N-acetylation, in 63% yield. The key intermediate <bold>60</bold> was obtained after hydrolysis
                    with LiOH, which simultaneously led to the removal of the O-3 acetyl group and lactic acid
                    formation, in 69% yield.
                </p>
                <p>Disaccharide <bold>60</bold> constitutes a versatile intermediate, allowing further regioselective
                    manipulation at O-3 and O-4 (after arylidene ring opening) positions, as well as the insertion of a
                    peptide chain at the lactate moiety.
                </p>
                <p>Accordingly, NAG-NAM disaccharide <bold>61</bold> was obtained in quantitative yield by hydrogenation
                    using Pd(OH)<sub>2</sub> on charcoal (removal of the benzyl groups at the O-1 and O-6 positions of
                    the muramyl residue and the benzylidene ring at the O-6 and O-4 positions of the NAG unit).
                </p>
                <p>Disaccharide <bold>60</bold> was also used to prepare the glycopeptide <bold>62</bold> by coupling
                    with a pentapeptide, previously attained via solid-phase synthesis using HMPB-AM resin, followed by
                    cleavage from the resin upon treatment with trifluoroacetic acid solution.
                </p>
                <p>This work was a follow-up to previous approaches reported by us, such as one-pot regioselective
                    protection and orthogonal approaches towards key intermediates to achieve NAG-NAM moieties [<xref
                            rid="B14-pharmaceuticals-13-00392" ref-type="bibr">14</xref>,<xref
                            rid="B72-pharmaceuticals-13-00392" ref-type="bibr">72</xref>]. In this approach, the
                    conjugation of the different protecting groups allowed for a shorter synthetic sequence and a
                    complete removal of protecting groups in a late stage of the synthesis. In particular, the choice of
                    the anomeric benzyl group facilitated the removal of protecting groups in one step. This work
                    represents a useful route to obtain the NAG-NAM disaccharide moiety, as well as non-natural
                    derivatives.
                </p>
            </sec>
            <sec id="sec4-pharmaceuticals-13-00392">
                <title>4. Synthetic Approaches towards the Carbohydrate Backbone of PGN from Biopolymers</title>
                <p>In the previous section, we described the different approaches developed to address the synthesis of
                    the complex PGN structure from a scaffold of residues of NAG derivatives. The main difficulty in the
                    synthesis of PGN fragments involves stereoselective glycosylation involving NAG derivatives [<xref
                            rid="B10-pharmaceuticals-13-00392" ref-type="bibr">10</xref>,<xref
                            rid="B73-pharmaceuticals-13-00392" ref-type="bibr">73</xref>,<xref
                            rid="B74-pharmaceuticals-13-00392" ref-type="bibr">74</xref>]. Approaches to assembling the
                    complex PGN fragments have been described, and include one-pot regioselective protection and
                    orthogonal approaches to achieve key intermediates as precursors of NAG-NAM moieties [<xref
                            rid="B12-pharmaceuticals-13-00392" ref-type="bibr">12</xref>,<xref
                            rid="B14-pharmaceuticals-13-00392" ref-type="bibr">14</xref>,<xref
                            rid="B15-pharmaceuticals-13-00392" ref-type="bibr">15</xref>,<xref
                            rid="B16-pharmaceuticals-13-00392" ref-type="bibr">16</xref>,<xref
                            rid="B17-pharmaceuticals-13-00392" ref-type="bibr">17</xref>,<xref
                            rid="B61-pharmaceuticals-13-00392" ref-type="bibr">61</xref>,<xref
                            rid="B63-pharmaceuticals-13-00392" ref-type="bibr">63</xref>,<xref
                            rid="B65-pharmaceuticals-13-00392" ref-type="bibr">65</xref>,<xref
                            rid="B70-pharmaceuticals-13-00392" ref-type="bibr">70</xref>,<xref
                            rid="B71-pharmaceuticals-13-00392" ref-type="bibr">71</xref>,<xref
                            rid="B75-pharmaceuticals-13-00392" ref-type="bibr">75</xref>,<xref
                            rid="B76-pharmaceuticals-13-00392" ref-type="bibr">76</xref>].
                </p>
                <p>We and others have been focused on establishing straightforward routes to achieve PGN fragments and
                    also on protection–deprotection methodologies of NAG-containing saccharides (<xref ref-type="scheme"
                                                                                                       rid="pharmaceuticals-13-00392-sch010">
                        Scheme 10</xref>) [<xref rid="B12-pharmaceuticals-13-00392" ref-type="bibr">12</xref>,<xref
                            rid="B61-pharmaceuticals-13-00392" ref-type="bibr">61</xref>,<xref
                            rid="B63-pharmaceuticals-13-00392" ref-type="bibr">63</xref>,<xref
                            rid="B65-pharmaceuticals-13-00392" ref-type="bibr">65</xref>,<xref
                            rid="B70-pharmaceuticals-13-00392" ref-type="bibr">70</xref>,<xref
                            rid="B71-pharmaceuticals-13-00392" ref-type="bibr">71</xref>,<xref
                            rid="B72-pharmaceuticals-13-00392" ref-type="bibr">72</xref>,<xref
                            rid="B75-pharmaceuticals-13-00392" ref-type="bibr">75</xref>,<xref
                            rid="B76-pharmaceuticals-13-00392" ref-type="bibr">76</xref>]. All these synthetic methods
                    involve a high number of steps required to achieve a key intermediate that possesses the lactyl
                    moiety installed at the O-3 position of the NAG moiety. These long multistep sequences are a
                    puzzling game of compatible protecting groups, due to the difficulties associated with the
                    establishment of the β-1,4 glyosidic bond of NAG-NAM. The success of a particular synthetic sequence
                    relies on the proper choice of protecting groups, in particular the N-protecting group (e.g., Troc,
                    TCP, MDM) [<xref rid="B14-pharmaceuticals-13-00392" ref-type="bibr">14</xref>,<xref
                            rid="B77-pharmaceuticals-13-00392" ref-type="bibr">77</xref>,<xref
                            rid="B78-pharmaceuticals-13-00392" ref-type="bibr">78</xref>], which enable enantioselective
                    control over glycosylation, as well as regioselective insertion of the lactyl moiety at the O-3
                    position of a modified and alternated (in the case of oligosaccharides) NAG unit.
                </p>
                <p>During recent years, our group embraced the challenge of synthetizing NAG-NAM containing
                    oligosaccharides and its precursors, using as starting material biopolymers, with the β-1,4
                    glycosidic bond already installed.
                </p>
                <p>In order to explore unprecedented synthetic studies, in order to develop alternatives to the
                    synthesis of PGN fragments, we were inspired by the particular sugar arrangement of PGN (<xref
                            ref-type="fig" rid="pharmaceuticals-13-00392-f001">Figure 1</xref>) and its resemblance to
                    other biopolymers found in nature, such as chitin and chitosan. Chitin is one of the most abundant
                    biopolymers in the world and consists of β-(1,4)-<italic toggle="yes">N</italic>-acetylglucosamine
                    (NAG), sharing the same basic carbohydrate backbone as that of PGN.
                </p>
                <p>In 2018 we established a procedure to achieve an advanced precursor of the NAG-NAM unit via
                    orthogonal synthesis, from peracetylated chitobiose, obtained after chitin chemical hydrolysis, as
                    shown in <xref ref-type="scheme" rid="pharmaceuticals-13-00392-sch011">Scheme 11</xref> [<xref
                            rid="B79-pharmaceuticals-13-00392" ref-type="bibr">79</xref>].
                </p>
                <p>Peracetylated chitobiose <bold>63</bold> was obtained on a gram scale from the chemical and
                    controlled depolimerization of chitin via acetolysis [<xref rid="B80-pharmaceuticals-13-00392"
                                                                                ref-type="bibr">80</xref>,<xref
                            rid="B81-pharmaceuticals-13-00392" ref-type="bibr">81</xref>], using an improved procedure
                    from that originally described by Beau at al. [<xref rid="B82-pharmaceuticals-13-00392"
                                                                         ref-type="bibr">82</xref>].
                </p>
                <p>We performed chemoselective <italic toggle="yes">N</italic>-<italic toggle="yes">trans</italic>-acylation
                    using a reported protocol [<xref rid="B82-pharmaceuticals-13-00392" ref-type="bibr">82</xref>], and
                    converted <bold>63</bold> into the <italic toggle="yes">N</italic>-trifluoroacetyl derivative
                    (NHTFA). This modification relied on direct and chemoselective N-<italic toggle="yes">trans</italic>-acylation
                    by the reaction of <bold>63</bold> with trifluoroacetyl anhydride, allowing an increased solubility,
                    while facilitating the following steps. Next, we produced disaccharide <bold>64</bold> by installing
                    the STolyl (STol) group at the anomeric position, using <italic toggle="yes">p</italic>-methylthiophenol
                    under BF<sub>3</sub>·OEt<sub>2</sub> conditions, in 80% yield. Methanolysis of <bold>64</bold> and
                    successive protection of 3,4-O positions with the butane-2,3-diacetal moiety and protection of O-6
                    with TBDMS, using TBDMSCl, TEA, and DMAP in DMF for 16 h afforded the corresponding product. This
                    procedure was executed in 56% yield.
                </p>
                <p>In our first attempts, we were not successful when introducing the lactyl moiety directly into the
                    precursor possessing the NTFA group. Thus, to avoid the random introduction of the lactate moiety,
                    the NTFA group was replaced by the NAc group, by treatment with NaOH in THF at 80 °C, followed
                    by <italic toggle="yes">N</italic>-acetylation with acetic anhydride in pyridine, affording <bold>
                        65
                    </bold> in 56% yield. The lactyl unit was then introduced by treatment of <bold>65</bold> with
                    propionic ester triflate, and <bold>66</bold> was attained in 38% yield. Intermediate <bold>66
                    </bold> possesses all functional groups (<italic toggle="yes">O</italic>-lactyl and NAc) required to
                    prepare the NAG-NAM disaccharide, constituting an excellent precursor of this moiety.
                </p>
                <p>In our strategy, we took advantage of the already established β-1,4 glycosidic bond present in the
                    easily-obtained peracetylated chitobiose <bold>63</bold>, avoiding one of the most challenging steps
                    in the synthesis of PGN fragments. This strategy resulted in a considerable reduction of the number
                    of steps required to obtain a NAG-NAM-containing disaccharide, constituting an atom-economy
                    procedure.
                </p>
                <p>In the follow-up of our synthesis of an advanced NAG-NAM precursor from chitobiose, we next reported
                    the synthesis of NAG-NAM-containing oligosaccharides from chitosan via a top-down approach involving
                    both chemical and enzymatic reactions (<xref ref-type="scheme"
                                                                 rid="pharmaceuticals-13-00392-sch012">Scheme 12</xref>)
                    [<xref rid="B83-pharmaceuticals-13-00392" ref-type="bibr">83</xref>]. This new route was able to
                    overcome the difficulties in obtaining sufficient long fragments to replace samples of biological
                    origin, which also constituted a limitation for further biological investigations [<xref
                            rid="B9-pharmaceuticals-13-00392" ref-type="bibr">9</xref>].
                </p>
                <p>Given the natural resemblance between the carbohydrate backbone of the PGN and chitosan, we envisaged
                    that a properly functionalized chitosan derivative would provide a suitable platform for an
                    alternate attachment of the Lac unit. This new polymer, after removal of the protecting groups,
                    could then be recognized as a PGN substrate by enzymes involved in the degradation of bacterial PGN
                    [<xref rid="B84-pharmaceuticals-13-00392" ref-type="bibr">84</xref>,<xref
                            rid="B85-pharmaceuticals-13-00392" ref-type="bibr">85</xref>,<xref
                            rid="B86-pharmaceuticals-13-00392" ref-type="bibr">86</xref>,<xref
                            rid="B87-pharmaceuticals-13-00392" ref-type="bibr">87</xref>], which would afford the
                    production of smaller oligosaccharides containing NAG-NAM units. PGN hydrolases, such as lysozyme or
                    mutanolysin, can efficiently hydrolyze the β-1,4 glycosidic bond in the natural PGN substrate,
                    between NAM and NAG residues [<xref rid="B84-pharmaceuticals-13-00392" ref-type="bibr">
                        84</xref>,<xref rid="B85-pharmaceuticals-13-00392" ref-type="bibr">85</xref>,<xref
                            rid="B86-pharmaceuticals-13-00392" ref-type="bibr">86</xref>,<xref
                            rid="B87-pharmaceuticals-13-00392" ref-type="bibr">87</xref>,<xref
                            rid="B88-pharmaceuticals-13-00392" ref-type="bibr">88</xref>] and in certain conditions and
                    to some extent in chitin and derivatives [<xref rid="B89-pharmaceuticals-13-00392" ref-type="bibr">
                        89</xref>,<xref rid="B90-pharmaceuticals-13-00392" ref-type="bibr">90</xref>].
                </p>
                <p>We initiated the synthesis by using the phthaloyl group as the N-protecting group of the commercial
                    chitosan, preventing the problems associated with the poor nucleophilicity of NAG derivatives. In
                    order to promote the attachment of the Lac unit in alternate glucosamine units, we explored the use
                    of a molecular clamp strategy, consisting of the formation of a stable bridge between two 6-OH
                    positions of alternate glucosamine units via an ester linkage. Thus, two clamps were synthesized
                    possessing different lengths <bold>C1</bold> (m = 1) and <bold>C2</bold> (m = 2). Different amounts
                    of <bold>C1</bold> and <bold>C2</bold> were tested to maximize the attachment of the Lac moiety in
                    alternate positions. Thus, treatment of the <italic toggle="yes">N</italic>-phthaloyl chitosan with
                    pre-activated acids <bold>C1</bold> or <bold>C2</bold> with CDI in DMF led to the formation of
                    compounds <bold>67</bold>. In order to prevent the introduction of Lac moieties in NAG residues that
                    had not reacted with clamps <bold>C1</bold> and <bold>C2</bold>, compounds <bold>67</bold> were
                    further silylated at the remaining free 6-OH positions by reaction with TBDMSCl in the presence of
                    imidazole, in DMF. Next, we performed the introduction of the Lac moiety, by treatment with NaH in
                    DMF, using (<italic toggle="yes">S</italic>)-(−)2-chloropropionic acid under different conditions
                    and equivalents, affording compounds <bold>68a</bold>–<bold>d</bold>. The sequential removal of the
                    phthalimide group by treatment with hydrazine solution and simultaneous removal of the ester clamp,
                    followed by N-acetylation with acetic anhydride and finally silyl group removal, by treatment with a
                    TBAF solution, afforded compounds <bold>69a</bold>–<bold>d</bold>. Due to the polymeric character of
                    the substrates, the structural characterization was performed by FT-IR and <sup>13</sup>C CP/MAS NMR
                    (cross polarization magic angle spinning nuclear magnetic resonance).
                </p>
                <p>The ratio of NAM/NAG in samples <bold>69a</bold>–<bold>d</bold> was determined by high performance
                    anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) and compared
                    with values determined in samples of bacterial PGN purified from <italic toggle="yes">Staphylococcus
                        aureus
                    </italic> and <italic toggle="yes">Escherichia coli</italic> (values of 1.2 and 1, respectively,
                    used as positive controls). We found that the NAM/NAG ratio determined in samples <bold>69a</bold>–<bold>
                        d
                    </bold> was dependent on the amounts of <bold>C1</bold>/<bold>C2</bold> and loadings of the (<italic
                            toggle="yes">S</italic>)-(−)2-chloropropionic acid used in our synthetic procedure. The best
                    results were obtained when a higher loading of C1, together with 2 equiv. of (<italic toggle="yes">
                        S</italic>)-(−)2-chloropropionic acid, were used. The sample <bold>69</bold> produced in these
                    conditions had a NAM/NAG ratio of 1.21, similar to that found in bacterial PGN purified from <italic
                            toggle="yes">Staphylococcus aureus
                    </italic> bacteria.
                </p>
                <p>Having confirmed that our synthetic procedures were able to result in a significant incorporation of
                    NAM residues on the chitosan skeleton, indicated by the ratio of NAM/NAG, we next investigated
                    whether alternated NAM units had been installed. This was performed by using PGN lytic enzymes, such
                    as mutanolysin and lysozyme, and by analysis of the fragments released by LC-MS. We found that 55%
                    of the digested <bold>69</bold> generated the disaccharide NAG-NAM in 7% yield, as well as the
                    trisaccharide NAG-NAG-NAM in 33% yield.
                </p>
                <p>This work highlights that the combination of chemical and chemical/enzymatic approaches is an
                    extremely attractive option, compared to traditional orthogonal synthesis, in the synthesis of
                    complex and biological important molecules. Of note, several enzymatic strategies, which use
                    particular purified bacterial enzymes for the production of PGN precursors/fragments, have also been
                    recently developed [<xref rid="B91-pharmaceuticals-13-00392" ref-type="bibr">91</xref>,<xref
                            rid="B92-pharmaceuticals-13-00392" ref-type="bibr">92</xref>,<xref
                            rid="B93-pharmaceuticals-13-00392" ref-type="bibr">93</xref>].
                </p>
            </sec>
            <sec sec-type="conclusions" id="sec5-pharmaceuticals-13-00392">
                <title>5. Conclusions</title>
                <p>PGN is a major constituent of the bacterial cell wall. Although its biosynthesis is assisted by
                    several enzymes that sequentially transform specific sugar precursors and assemble them into the
                    complex structure of the natural PGN, its chemical synthesis poses several problems. Despite all
                    efforts developed by us and others, the synthesis of PGN fragments remains a challenge. The key
                    difficulty is based on stereoselective glycosylation involving NAG derivatives. Indeed, the complex
                    synthesis of the carbohydrate backbone commonly involves multistep sequences to install the lactyl
                    moiety at the O-3 position and to control enantioselective glycosylation.
                </p>
                <p>This review presents the biosynthetic pathways, as well as covering several approaches used to
                    assemble the complex PGN fragments, including one-pot regioselective protection, orthogonal
                    approaches, and the recently reported chemoenzymatic route towards key intermediates to achieve
                    NAG-NAM moieties.
                </p>
                <p>The synthesis of bacterial PGN fragments is crucial in order to better understand the role of this
                    macromolecule in the metabolism of bacteria and their recognition by different hosts. This review
                    collects the approaches, the difficulties imposed by the natural PGN structure, and the discoveries
                    made by the community to address the synthesis of PGN molecules.
                </p>
            </sec>
        </body>
        <back>
            <ack>
                <title>Acknowledgments</title>
                <p>The authors acknowledge the Fundação para a Ciência e Tecnologia (FC&amp;T) for the fellowships
                    SFRH/BD/89518/2012, SFRH/BD/52207/2013 (to FQ and GC) and for the projects (PTDC/QEQ-QOR/2132/2012,
                    PTDC/BIA-MIC/30746/2017 and UID/DTP/04138/2013). This work was supported by the Associate Laboratory
                    for Green Chemistry, LAQV, which is financed by national funds from FCT/MCTES (UID/QUI/50006/2019)
                    and co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER—007265). We
                    also acknowledge the support from Applied Molecular Biosciences Unit-UCIBIO, which is financed by
                    national funds from FCT/MCTES (UID/Multi/04378/2019).
                </p>
            </ack>
            <fn-group>
                <fn>
                    <p>
                        <bold>Publisher’s Note:</bold>
                        MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
                        affiliations.
                    </p>
                </fn>
            </fn-group>
            <notes>
                <title>Author Contributions</title>
                <p>All authors have equally contributed to this review, G.C. and S.R.F. are responsible for the
                    subchapter of the biosynthesis of PGN; and F.Q. and M.M.B.M. contributed for the sections dedicated
                    to the synthetic approaches to fragments of PGN. All authors have read and agreed to the published
                    version of the manuscript.
                </p>
            </notes>
            <notes>
                <title>Funding</title>
                <p>This research received no external funding.</p>
            </notes>
            <notes notes-type="COI-statement">
                <title>Conflicts of Interest</title>
                <p>The authors declare no conflict of interest.</p>
            </notes>
            <ref-list>
                <title>References</title>
                <ref id="B1-pharmaceuticals-13-00392">
                    <label>1.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Schleifer</surname>
                                <given-names>K.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kandler</surname>
                                <given-names>O.</given-names>
                            </name>
                        </person-group>
                        <article-title>Peptidoglycan types of bacterial cell-walls and their taxonomic implications
                        </article-title>
                        <source>Bacteriol. Rev.</source>
                        <year>1972</year>
                        <volume>36</volume>
                        <fpage>407</fpage>
                        <lpage>477</lpage>
                        <pub-id pub-id-type="doi">10.1128/MMBR.36.4.407-477.1972</pub-id>
                        <pub-id pub-id-type="pmid">4568761</pub-id>
                        <pub-id pub-id-type="pmcid">PMC408328</pub-id>
                    </element-citation>
                </ref>
                <ref id="B2-pharmaceuticals-13-00392">
                    <label>2.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Holtje</surname>
                                <given-names>J.V.</given-names>
                            </name>
                        </person-group>
                        <article-title>Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia
                            coli
                        </article-title>
                        <source>Microbiol. Mol. Biol. Rev.</source>
                        <year>1998</year>
                        <volume>62</volume>
                        <fpage>181</fpage>
                        <pub-id pub-id-type="doi">10.1128/MMBR.62.1.181-203.1998</pub-id>
                        <pub-id pub-id-type="pmid">9529891</pub-id>
                        <pub-id pub-id-type="pmcid">PMC98910</pub-id>
                    </element-citation>
                </ref>
                <ref id="B3-pharmaceuticals-13-00392">
                    <label>3.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Roemer</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Schneider</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pinho</surname>
                                <given-names>M.G.</given-names>
                            </name>
                        </person-group>
                        <article-title>Auxiliary factors: A chink in the armor of MRSA resistance to beta-lactam
                            antibiotics
                        </article-title>
                        <source>Curr. Opin. Microbiol.</source>
                        <year>2013</year>
                        <volume>16</volume>
                        <fpage>538</fpage>
                        <lpage>548</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.mib.2013.06.012</pub-id>
                        <pub-id pub-id-type="pmid">23895826</pub-id>
                    </element-citation>
                </ref>
                <ref id="B4-pharmaceuticals-13-00392">
                    <label>4.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Courvalin</surname>
                                <given-names>P.</given-names>
                            </name>
                        </person-group>
                        <article-title>Vancomycin resistance in gram-positive cocci</article-title>
                        <source>Clin. Infect. Dis.</source>
                        <year>2006</year>
                        <volume>42</volume>
                        <fpage>S25</fpage>
                        <lpage>S34</lpage>
                        <pub-id pub-id-type="doi">10.1086/491711</pub-id>
                        <pub-id pub-id-type="pmid">16323116</pub-id>
                    </element-citation>
                </ref>
                <ref id="B5-pharmaceuticals-13-00392">
                    <label>5.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Kohanski</surname>
                                <given-names>M.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dwyer</surname>
                                <given-names>D.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Collins</surname>
                                <given-names>J.J.</given-names>
                            </name>
                        </person-group>
                        <article-title>How antibiotics kill bacteria: From targets to networks</article-title>
                        <source>Nat. Rev. Microbiol.</source>
                        <year>2010</year>
                        <volume>8</volume>
                        <fpage>423</fpage>
                        <lpage>435</lpage>
                        <pub-id pub-id-type="doi">10.1038/nrmicro2333</pub-id>
                        <pub-id pub-id-type="pmid">20440275</pub-id>
                        <pub-id pub-id-type="pmcid">PMC2896384</pub-id>
                    </element-citation>
                </ref>
                <ref id="B6-pharmaceuticals-13-00392">
                    <label>6.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Vollmer</surname>
                                <given-names>W.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Joris</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Charlier</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Foster</surname>
                                <given-names>S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Bacterial peptidoglycan (murein) hydrolases</article-title>
                        <source>Fems Microbiol. Rev.</source>
                        <year>2008</year>
                        <volume>32</volume>
                        <fpage>259</fpage>
                        <lpage>286</lpage>
                        <pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00099.x</pub-id>
                        <pub-id pub-id-type="pmid">18266855</pub-id>
                    </element-citation>
                </ref>
                <ref id="B7-pharmaceuticals-13-00392">
                    <label>7.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Cho</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Uehara</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bernhardt</surname>
                                <given-names>T.G.</given-names>
                            </name>
                        </person-group>
                        <article-title>Beta-Lactam Antibiotics Induce a Lethal Malfunctioning of the Bacterial Cell Wall
                            Synthesis Machinery
                        </article-title>
                        <source>Cell</source>
                        <year>2014</year>
                        <volume>159</volume>
                        <fpage>1300</fpage>
                        <lpage>1311</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.017</pub-id>
                        <pub-id pub-id-type="pmid">25480295</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4258230</pub-id>
                    </element-citation>
                </ref>
                <ref id="B8-pharmaceuticals-13-00392">
                    <label>8.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Catalao</surname>
                                <given-names>M.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gil</surname>
                                <given-names>F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Moniz-Pereira</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Sao-Jose</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pimentel</surname>
                                <given-names>M.</given-names>
                            </name>
                        </person-group>
                        <article-title>Diversity in bacterial lysis systems: Bacteriophages show the way</article-title>
                        <source>Fems Microbiol. Rev.</source>
                        <year>2013</year>
                        <volume>37</volume>
                        <fpage>554</fpage>
                        <lpage>571</lpage>
                        <pub-id pub-id-type="doi">10.1111/1574-6976.12006</pub-id>
                        <pub-id pub-id-type="pmid">23043507</pub-id>
                    </element-citation>
                </ref>
                <ref id="B9-pharmaceuticals-13-00392">
                    <label>9.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>L.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Weber</surname>
                                <given-names>A.N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Atilano</surname>
                                <given-names>M.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Filipe</surname>
                                <given-names>S.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gay</surname>
                                <given-names>N.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ligoxygakis</surname>
                                <given-names>P.</given-names>
                            </name>
                        </person-group>
                        <article-title>Sensing of Gram-positive bacteria in Drosophila: GNBP1 is needed to process and
                            present peptidoglycan to PGRP-SA
                        </article-title>
                        <source>Embo J.</source>
                        <year>2006</year>
                        <volume>25</volume>
                        <fpage>5005</fpage>
                        <lpage>5014</lpage>
                        <pub-id pub-id-type="doi">10.1038/sj.emboj.7601363</pub-id>
                        <pub-id pub-id-type="pmid">17024181</pub-id>
                        <pub-id pub-id-type="pmcid">PMC1618108</pub-id>
                    </element-citation>
                </ref>
                <ref id="B10-pharmaceuticals-13-00392">
                    <label>10.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Yang</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yu</surname>
                                <given-names>B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Recent advances in the synthesis of chitooligosaccharides and congeners
                        </article-title>
                        <source>Tetrahedron</source>
                        <year>2014</year>
                        <volume>70</volume>
                        <fpage>1023</fpage>
                        <lpage>1046</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.tet.2013.11.064</pub-id>
                    </element-citation>
                </ref>
                <ref id="B11-pharmaceuticals-13-00392">
                    <label>11.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Yang</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Liu</surname>
                                <given-names>T.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yang</surname>
                                <given-names>Y.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wu</surname>
                                <given-names>Q.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yang</surname>
                                <given-names>Q.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yu</surname>
                                <given-names>B.A.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis, Evaluation, and Mechanism of N,N,N-Trimethyl-D-glucosamine-(1 -&gt;
                            4)-chitooligosaccharides as Selective Inhibitors of Glycosyl Hydrolase Family 20
                            beta-N-Acetyl-D-hexosaminidases
                        </article-title>
                        <source>Chembiochem</source>
                        <year>2011</year>
                        <volume>12</volume>
                        <fpage>457</fpage>
                        <lpage>467</lpage>
                        <pub-id pub-id-type="doi">10.1002/cbic.201000561</pub-id>
                        <pub-id pub-id-type="pmid">21290547</pub-id>
                    </element-citation>
                </ref>
                <ref id="B12-pharmaceuticals-13-00392">
                    <label>12.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Shih</surname>
                                <given-names>H.W.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Chen</surname>
                                <given-names>K.T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Cheng</surname>
                                <given-names>T.J.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wong</surname>
                                <given-names>C.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Cheng</surname>
                                <given-names>W.C.</given-names>
                            </name>
                        </person-group>
                        <article-title>A New Synthetic Approach toward Bacterial Transglycosylase Substrates, Lipid II
                            and Lipid IV
                        </article-title>
                        <source>Org. Lett.</source>
                        <year>2011</year>
                        <volume>13</volume>
                        <fpage>4600</fpage>
                        <lpage>4603</lpage>
                        <pub-id pub-id-type="doi">10.1021/ol201806d</pub-id>
                        <pub-id pub-id-type="pmid">21797279</pub-id>
                    </element-citation>
                </ref>
                <ref id="B13-pharmaceuticals-13-00392">
                    <label>13.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Berthelot</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Brossay</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gasciolli</surname>
                                <given-names>V.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bono</surname>
                                <given-names>J.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Baron</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Beau</surname>
                                <given-names>J.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Urban</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boyer</surname>
                                <given-names>F.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vauzeilles</surname>
                                <given-names>B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of lipo-chitooligosaccharide analogues and their interaction with LYR3,
                            a high affinity binding protein for Nod factors and Myc-LCOs
                        </article-title>
                        <source>Org. Biomol. Chem.</source>
                        <year>2017</year>
                        <volume>15</volume>
                        <fpage>7802</fpage>
                        <lpage>7812</lpage>
                        <pub-id pub-id-type="doi">10.1039/C7OB01201B</pub-id>
                        <pub-id pub-id-type="pmid">28876013</pub-id>
                    </element-citation>
                </ref>
                <ref id="B14-pharmaceuticals-13-00392">
                    <label>14.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Enugala</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Carvalho</surname>
                                <given-names>L.C.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pires</surname>
                                <given-names>M.J.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Stereoselective Glycosylation of Glucosamine: The Role of the N-Protecting
                            Group
                        </article-title>
                        <source>Chem. Asian J.</source>
                        <year>2012</year>
                        <volume>7</volume>
                        <fpage>2482</fpage>
                        <lpage>2501</lpage>
                        <pub-id pub-id-type="doi">10.1002/asia.201200338</pub-id>
                        <pub-id pub-id-type="pmid">22753270</pub-id>
                    </element-citation>
                </ref>
                <ref id="B15-pharmaceuticals-13-00392">
                    <label>15.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Bongat</surname>
                                <given-names>A.F.G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Demchenko</surname>
                                <given-names>A.V.</given-names>
                            </name>
                        </person-group>
                        <article-title>Recent trends in the synthesis of O-glycosides of 2-amino-2-deoxysugars
                        </article-title>
                        <source>Carbohydr. Res.</source>
                        <year>2007</year>
                        <volume>342</volume>
                        <fpage>374</fpage>
                        <lpage>406</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.carres.2006.10.021</pub-id>
                        <pub-id pub-id-type="pmid">17125757</pub-id>
                    </element-citation>
                </ref>
                <ref id="B16-pharmaceuticals-13-00392">
                    <label>16.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Arihara</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Nakamura</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hashimoto</surname>
                                <given-names>S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Direct and stereoselective synthesis of
                            2-acetamido-2-deoxy-beta-D-glycopyranosides by using the phosphite method
                        </article-title>
                        <source>Angew. Chem. Int. Ed.</source>
                        <year>2005</year>
                        <volume>44</volume>
                        <fpage>2245</fpage>
                        <lpage>2249</lpage>
                        <pub-id pub-id-type="doi">10.1002/anie.200461988</pub-id>
                        <pub-id pub-id-type="pmid">15747388</pub-id>
                    </element-citation>
                </ref>
                <ref id="B17-pharmaceuticals-13-00392">
                    <label>17.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Stevenin</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boyer</surname>
                                <given-names>F.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Beau</surname>
                                <given-names>J.M.</given-names>
                            </name>
                        </person-group>
                        <article-title>Highly Selective Formation of beta-Glycosides of N-Acetylglucosamine Using
                            Catalytic Iron(III) Triflate
                        </article-title>
                        <source>Eur. J. Org. Chem.</source>
                        <year>2012</year>
                        <volume>2012</volume>
                        <fpage>1699</fpage>
                        <lpage>1702</lpage>
                        <pub-id pub-id-type="doi">10.1002/ejoc.201200062</pub-id>
                    </element-citation>
                </ref>
                <ref id="B18-pharmaceuticals-13-00392">
                    <label>18.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Crich</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dudkin</surname>
                                <given-names>V.</given-names>
                            </name>
                        </person-group>
                        <article-title>Why are the hydroxy groups of partially protected N-acetylglucosamine derivatives
                            such poor glycosyl accepters, and what can be done about it? A comparative study of the
                            reactivity of N-acetyl-, N-phthalimido-, and 2-azido-2-deoxy-glucosamine derivatives in
                            glycosylation. 2-picolinyl ethers as reactivity-enhancing replacements for benzyl ethers
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2001</year>
                        <volume>123</volume>
                        <fpage>6819</fpage>
                        <lpage>6825</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja010086b</pub-id>
                        <pub-id pub-id-type="pmid">11448186</pub-id>
                    </element-citation>
                </ref>
                <ref id="B19-pharmaceuticals-13-00392">
                    <label>19.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Badet</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vermoote</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Legoffic</surname>
                                <given-names>F.</given-names>
                            </name>
                        </person-group>
                        <article-title>Glucosamine synthetase from escherichia-coli kinetic mechanism and inhibition by
                            n3-fumaroyl-l-2,3-diaminopropionic derivatives
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1988</year>
                        <volume>27</volume>
                        <fpage>2282</fpage>
                        <lpage>2287</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi00407a006</pub-id>
                        <pub-id pub-id-type="pmid">3132968</pub-id>
                    </element-citation>
                </ref>
                <ref id="B20-pharmaceuticals-13-00392">
                    <label>20.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Badetdenisot</surname>
                                <given-names>M.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Badet</surname>
                                <given-names>B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Chemical modification of glucosamine-6-phosphate synthase by diethyl
                            pyrocarbonate—Evidence of histidine requirement for enzymatic-activity
                        </article-title>
                        <source>Arch. Biochem. Biophys.</source>
                        <year>1992</year>
                        <volume>292</volume>
                        <fpage>475</fpage>
                        <lpage>478</lpage>
                        <pub-id pub-id-type="doi">10.1016/0003-9861(92)90018-R</pub-id>
                        <pub-id pub-id-type="pmid">1731613</pub-id>
                    </element-citation>
                </ref>
                <ref id="B21-pharmaceuticals-13-00392">
                    <label>21.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Gehring</surname>
                                <given-names>A.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lees</surname>
                                <given-names>W.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mindiola</surname>
                                <given-names>D.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walsh</surname>
                                <given-names>C.T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Brown</surname>
                                <given-names>E.D.</given-names>
                            </name>
                        </person-group>
                        <article-title>Acetyltransfer precedes uridylyltransfer in the formation of
                            UDP-N-acetylglucosamine in separable active sites of the bifunctional GlmU protein of
                            Escherichia coli
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1996</year>
                        <volume>35</volume>
                        <fpage>579</fpage>
                        <lpage>585</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi952275a</pub-id>
                        <pub-id pub-id-type="pmid">8555230</pub-id>
                    </element-citation>
                </ref>
                <ref id="B22-pharmaceuticals-13-00392">
                    <label>22.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Jolly</surname>
                                <given-names>L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ferrari</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>van Heijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fassy</surname>
                                <given-names>F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mengin-Lecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                        </person-group>
                        <article-title>Reaction mechanism of phosphoglucosamine mutase from Escherichia coli
                        </article-title>
                        <source>Eur. J. Biochem.</source>
                        <year>1999</year>
                        <volume>262</volume>
                        <fpage>202</fpage>
                        <lpage>210</lpage>
                        <pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00373.x</pub-id>
                        <pub-id pub-id-type="pmid">10231382</pub-id>
                    </element-citation>
                </ref>
                <ref id="B23-pharmaceuticals-13-00392">
                    <label>23.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Menginlecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vanheijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Copurification of glucosamine-1-phosphate acetyltransferase and
                            n-acetylglucosamine-1-phosphate uridyltransferase activities of
                            escherichia-coli-characterization of the glmu gene-product as a bifunctional enzyme
                            catalyzing 2 subsequent steps in the pathway for udp-n-acetylglucosamine synthesis
                        </article-title>
                        <source>J. Bacteriol.</source>
                        <year>1994</year>
                        <volume>176</volume>
                        <fpage>5788</fpage>
                        <lpage>5795</lpage>
                        <pub-id pub-id-type="doi">10.1128/jb.176.18.5788-5795.1994</pub-id>
                        <pub-id pub-id-type="pmid">8083170</pub-id>
                        <pub-id pub-id-type="pmcid">PMC196783</pub-id>
                    </element-citation>
                </ref>
                <ref id="B24-pharmaceuticals-13-00392">
                    <label>24.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>MenginLecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>vanHeijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Characterization of the essential gene glmM encoding phosphoglucosamine mutase in
                            Escherichia coli
                        </article-title>
                        <source>J. Biol. Chem.</source>
                        <year>1996</year>
                        <volume>271</volume>
                        <fpage>32</fpage>
                        <lpage>39</lpage>
                        <pub-id pub-id-type="doi">10.1074/jbc.271.1.32</pub-id>
                        <pub-id pub-id-type="pmid">8550580</pub-id>
                    </element-citation>
                </ref>
                <ref id="B25-pharmaceuticals-13-00392">
                    <label>25.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Benson</surname>
                                <given-names>T.E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marquardt</surname>
                                <given-names>J.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marquardt</surname>
                                <given-names>A.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Etzkorn</surname>
                                <given-names>F.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walsh</surname>
                                <given-names>C.T.</given-names>
                            </name>
                        </person-group>
                        <article-title>Overexpression, purification, and mechanistic study of
                            udp-n-acetylenolpyruvylglucosamine reductase
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1993</year>
                        <volume>32</volume>
                        <fpage>2024</fpage>
                        <lpage>2030</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi00059a019</pub-id>
                        <pub-id pub-id-type="pmid">8448160</pub-id>
                    </element-citation>
                </ref>
                <ref id="B26-pharmaceuticals-13-00392">
                    <label>26.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Benson</surname>
                                <given-names>T.E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walsh</surname>
                                <given-names>C.T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Massey</surname>
                                <given-names>V.</given-names>
                            </name>
                        </person-group>
                        <article-title>Kinetic characterization of wild-type and S229A mutant MurB: Evidence for the
                            role of ser 229 as a general acid
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1997</year>
                        <volume>36</volume>
                        <fpage>796</fpage>
                        <lpage>805</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi962220o</pub-id>
                        <pub-id pub-id-type="pmid">9020777</pub-id>
                    </element-citation>
                </ref>
                <ref id="B27-pharmaceuticals-13-00392">
                    <label>27.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Krekel</surname>
                                <given-names>F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Samland</surname>
                                <given-names>A.K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Macheroux</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Amrhein</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Evans</surname>
                                <given-names>J.N.S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Determination of the pK(a) value of C115 in MurA (UDP-N-acetylglucosamine
                            enolpyruvyltransferase) from Enterobacter cloacae
                        </article-title>
                        <source>Biochemistry</source>
                        <year>2000</year>
                        <volume>39</volume>
                        <fpage>12671</fpage>
                        <lpage>12677</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi001310x</pub-id>
                        <pub-id pub-id-type="pmid">11027147</pub-id>
                    </element-citation>
                </ref>
                <ref id="B28-pharmaceuticals-13-00392">
                    <label>28.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Doublet</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vanheijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bohin</surname>
                                <given-names>J.P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Menginlecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                        </person-group>
                        <article-title>The muri gene of escherichia-coli is an essential gene that encodes a glutamate
                            racemase activity
                        </article-title>
                        <source>J. Bacteriol.</source>
                        <year>1993</year>
                        <volume>175</volume>
                        <fpage>2970</fpage>
                        <lpage>2979</lpage>
                        <pub-id pub-id-type="doi">10.1128/JB.175.10.2970-2979.1993</pub-id>
                        <pub-id pub-id-type="pmid">8098327</pub-id>
                        <pub-id pub-id-type="pmcid">PMC204615</pub-id>
                    </element-citation>
                </ref>
                <ref id="B29-pharmaceuticals-13-00392">
                    <label>29.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Doublet</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vanheijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Menginlecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                        </person-group>
                        <article-title>The glutamate racemase activity from escherichia-coli is regulated by
                            peptidoglycan precursor udp-n-acetylmuramoyl-l-alanine
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1994</year>
                        <volume>33</volume>
                        <fpage>5285</fpage>
                        <lpage>5290</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi00183a035</pub-id>
                        <pub-id pub-id-type="pmid">8172902</pub-id>
                    </element-citation>
                </ref>
                <ref id="B30-pharmaceuticals-13-00392">
                    <label>30.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Scaletti</surname>
                                <given-names>E.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Luckner</surname>
                                <given-names>S.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Krause</surname>
                                <given-names>K.L.</given-names>
                            </name>
                        </person-group>
                        <article-title>Structural features and kinetic characterization of alanine racemase from
                            Staphylococcus aureus (Mu50)
                        </article-title>
                        <source>Acta Crystallogr. Sect. D Struct. Biol.</source>
                        <year>2012</year>
                        <volume>68</volume>
                        <fpage>82</fpage>
                        <lpage>92</lpage>
                        <pub-id pub-id-type="doi">10.1107/S0907444911050682</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3245724</pub-id>
                        <pub-id pub-id-type="pmid">22194336</pub-id>
                    </element-citation>
                </ref>
                <ref id="B31-pharmaceuticals-13-00392">
                    <label>31.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Kouidmi</surname>
                                <given-names>I.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Levesque</surname>
                                <given-names>R.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Paradis-Bleau</surname>
                                <given-names>C.</given-names>
                            </name>
                        </person-group>
                        <article-title>The biology of Mur ligases as an antibacterial target</article-title>
                        <source>Mol. Microbiol.</source>
                        <year>2014</year>
                        <volume>94</volume>
                        <fpage>242</fpage>
                        <lpage>253</lpage>
                        <pub-id pub-id-type="doi">10.1111/mmi.12758</pub-id>
                        <pub-id pub-id-type="pmid">25130693</pub-id>
                    </element-citation>
                </ref>
                <ref id="B32-pharmaceuticals-13-00392">
                    <label>32.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Ruane</surname>
                                <given-names>K.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lloyd</surname>
                                <given-names>A.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fulop</surname>
                                <given-names>V.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dowson</surname>
                                <given-names>C.G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Barreteau</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boniface</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dementin</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mengin-Lecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gobec</surname>
                                <given-names>S.</given-names>
                            </name>
                            <etal/>
                        </person-group>
                        <article-title>Specificity Determinants for Lysine Incorporation in Staphylococcus aureus
                            Peptidoglycan as Revealed by the Structure of a MurE Enzyme Ternary Complex
                        </article-title>
                        <source>J. Biol. Chem.</source>
                        <year>2013</year>
                        <volume>288</volume>
                        <fpage>33439</fpage>
                        <lpage>33448</lpage>
                        <pub-id pub-id-type="doi">10.1074/jbc.M113.508135</pub-id>
                        <pub-id pub-id-type="pmid">24064214</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3829189</pub-id>
                    </element-citation>
                </ref>
                <ref id="B33-pharmaceuticals-13-00392">
                    <label>33.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Bertrand</surname>
                                <given-names>J.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Auger</surname>
                                <given-names>G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Martin</surname>
                                <given-names>L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fanchon</surname>
                                <given-names>E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>La Beller</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>van Heijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dideberg</surname>
                                <given-names>O.</given-names>
                            </name>
                        </person-group>
                        <article-title>Determination of the MurD mechanism through crystallographic analysis of enzyme
                            complexes
                        </article-title>
                        <source>J. Mol. Biol.</source>
                        <year>1999</year>
                        <volume>289</volume>
                        <fpage>579</fpage>
                        <lpage>590</lpage>
                        <pub-id pub-id-type="doi">10.1006/jmbi.1999.2800</pub-id>
                        <pub-id pub-id-type="pmid">10356330</pub-id>
                    </element-citation>
                </ref>
                <ref id="B34-pharmaceuticals-13-00392">
                    <label>34.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Emanuele</surname>
                                <given-names>J.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Jin</surname>
                                <given-names>H.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Jacobson</surname>
                                <given-names>B.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Chang</surname>
                                <given-names>C.Y.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Einspahr</surname>
                                <given-names>H.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Villafranca</surname>
                                <given-names>J.J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Kinetic and crystallographic studies of Escherichia coli UDP-N-acetylmuramate:
                            L-alanine ligase
                        </article-title>
                        <source>Protein Sci.</source>
                        <year>1996</year>
                        <volume>5</volume>
                        <fpage>2566</fpage>
                        <lpage>2574</lpage>
                        <pub-id pub-id-type="doi">10.1002/pro.5560051219</pub-id>
                        <pub-id pub-id-type="pmid">8976565</pub-id>
                        <pub-id pub-id-type="pmcid">PMC2143315</pub-id>
                    </element-citation>
                </ref>
                <ref id="B35-pharmaceuticals-13-00392">
                    <label>35.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Zawadzke</surname>
                                <given-names>L.E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bugg</surname>
                                <given-names>T.D.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walsh</surname>
                                <given-names>C.T.</given-names>
                            </name>
                        </person-group>
                        <article-title>Existence of 2 d-alanine-d-alanine ligases in escherichia-coli-cloning and
                            sequencing of the ddla gene and purification and characterization of the ddla and ddlb
                            enzymes
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1991</year>
                        <volume>30</volume>
                        <fpage>1673</fpage>
                        <lpage>1682</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi00220a033</pub-id>
                        <pub-id pub-id-type="pmid">1993184</pub-id>
                    </element-citation>
                </ref>
                <ref id="B36-pharmaceuticals-13-00392">
                    <label>36.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Anderson</surname>
                                <given-names>M.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Eveland</surname>
                                <given-names>S.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Onishi</surname>
                                <given-names>H.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pompliano</surname>
                                <given-names>D.L.</given-names>
                            </name>
                        </person-group>
                        <article-title>Kinetic mechanism of the Escherichia coli UDPMurNAc-tripeptide
                            D-alanyl-D-alanine-adding enzyme: Use of a glutathione S-transferase fusion
                        </article-title>
                        <source>Biochemistry</source>
                        <year>1996</year>
                        <volume>35</volume>
                        <fpage>16264</fpage>
                        <lpage>16269</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi961872+</pub-id>
                        <pub-id pub-id-type="pmid">8973200</pub-id>
                    </element-citation>
                </ref>
                <ref id="B37-pharmaceuticals-13-00392">
                    <label>37.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Albar</surname>
                                <given-names>O.A.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Oconnor</surname>
                                <given-names>C.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Giles</surname>
                                <given-names>I.G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Akhtar</surname>
                                <given-names>M.</given-names>
                            </name>
                        </person-group>
                        <article-title>D-alanine-d-alanine ligase of escherichia-coli-expression, purification and
                            inhibitory studies on the cloned enzyme
                        </article-title>
                        <source>Biochem. J.</source>
                        <year>1992</year>
                        <volume>282</volume>
                        <fpage>747</fpage>
                        <lpage>752</lpage>
                        <pub-id pub-id-type="doi">10.1042/bj2820747</pub-id>
                        <pub-id pub-id-type="pmid">1554356</pub-id>
                        <pub-id pub-id-type="pmcid">PMC1130851</pub-id>
                    </element-citation>
                </ref>
                <ref id="B38-pharmaceuticals-13-00392">
                    <label>38.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Al-Dabbagh</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Henry</surname>
                                <given-names>X.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>El Ghachi</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Auger</surname>
                                <given-names>G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Parquet</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mengin-Lecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bouhss</surname>
                                <given-names>A.</given-names>
                            </name>
                        </person-group>
                        <article-title>Active site mapping of MraY, a member of the polyprenyl-phosphate
                            N-acetylhexosamine 1-phosphate transferase superfamily, catalyzing the first membrane step
                            of peptidoglycan biosynthesis
                        </article-title>
                        <source>Biochemistry</source>
                        <year>2008</year>
                        <volume>47</volume>
                        <fpage>8919</fpage>
                        <lpage>8928</lpage>
                        <pub-id pub-id-type="doi">10.1021/bi8006274</pub-id>
                        <pub-id pub-id-type="pmid">18672909</pub-id>
                    </element-citation>
                </ref>
                <ref id="B39-pharmaceuticals-13-00392">
                    <label>39.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Chung</surname>
                                <given-names>B.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Zhao</surname>
                                <given-names>J.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gillespie</surname>
                                <given-names>R.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kwon</surname>
                                <given-names>D.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Guan</surname>
                                <given-names>Z.Q.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hong</surname>
                                <given-names>J.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Zhou</surname>
                                <given-names>P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lee</surname>
                                <given-names>S.Y.</given-names>
                            </name>
                        </person-group>
                        <article-title>Crystal Structure of MraY, an Essential Membrane Enzyme for Bacterial Cell Wall
                            Synthesis
                        </article-title>
                        <source>Science</source>
                        <year>2013</year>
                        <volume>341</volume>
                        <fpage>1012</fpage>
                        <lpage>1016</lpage>
                        <pub-id pub-id-type="doi">10.1126/science.1236501</pub-id>
                        <pub-id pub-id-type="pmid">23990562</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3906829</pub-id>
                    </element-citation>
                </ref>
                <ref id="B40-pharmaceuticals-13-00392">
                    <label>40.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Bouhss</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Crouvoisier</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mengin-Lecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                        </person-group>
                        <article-title>Purification and characterization of the bacterial MraY translocase catalyzing
                            the first membrane step of peptidoglycan biosynthesis
                        </article-title>
                        <source>J. Biol. Chem.</source>
                        <year>2004</year>
                        <volume>279</volume>
                        <fpage>29974</fpage>
                        <lpage>29980</lpage>
                        <pub-id pub-id-type="doi">10.1074/jbc.M314165200</pub-id>
                        <pub-id pub-id-type="pmid">15131133</pub-id>
                    </element-citation>
                </ref>
                <ref id="B41-pharmaceuticals-13-00392">
                    <label>41.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Anderson</surname>
                                <given-names>J.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Matsuhashi</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Haskin</surname>
                                <given-names>M.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Strominger</surname>
                                <given-names>J.L.</given-names>
                            </name>
                        </person-group>
                        <article-title>Lipid-phosphoacetylmuramyl-pentapeptide and
                            lipid-phosphodisaccharide-pentapeptide–presumed membrane transport intermediates in cell
                            wall synthesis
                        </article-title>
                        <source>Proc. Natl. Acad. Sci. USA</source>
                        <year>1965</year>
                        <volume>53</volume>
                        <fpage>881</fpage>
                        <pub-id pub-id-type="doi">10.1073/pnas.53.4.881</pub-id>
                        <pub-id pub-id-type="pmid">14324547</pub-id>
                        <pub-id pub-id-type="pmcid">PMC221083</pub-id>
                    </element-citation>
                </ref>
                <ref id="B42-pharmaceuticals-13-00392">
                    <label>42.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>van Heijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Lipid intermediates in the biosynthesis of bacterial peptidoglycan
                        </article-title>
                        <source>Microbiol. Mol. Biol. Rev.</source>
                        <year>2007</year>
                        <volume>71</volume>
                        <fpage>620</fpage>
                        <pub-id pub-id-type="doi">10.1128/MMBR.00016-07</pub-id>
                        <pub-id pub-id-type="pmid">18063720</pub-id>
                        <pub-id pub-id-type="pmcid">PMC2168651</pub-id>
                    </element-citation>
                </ref>
                <ref id="B43-pharmaceuticals-13-00392">
                    <label>43.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Menginlecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Texier</surname>
                                <given-names>L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Rousseau</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vanheijenoort</surname>
                                <given-names>J.</given-names>
                            </name>
                        </person-group>
                        <article-title>The murg gene of escherichia-coli codes for the
                            udp-n-acetylglucosamine-n-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol
                            n-acetylglucosamine transferase involved in the membrane steps of peptidoglycan synthesis
                        </article-title>
                        <source>J. Bacteriol.</source>
                        <year>1991</year>
                        <volume>173</volume>
                        <fpage>4625</fpage>
                        <lpage>4636</lpage>
                        <pub-id pub-id-type="doi">10.1128/JB.173.15.4625-4636.1991</pub-id>
                        <pub-id pub-id-type="pmid">1649817</pub-id>
                        <pub-id pub-id-type="pmcid">PMC208138</pub-id>
                    </element-citation>
                </ref>
                <ref id="B44-pharmaceuticals-13-00392">
                    <label>44.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Mohammadi</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>van Dam</surname>
                                <given-names>V.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Sijbrandi</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vernet</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Zapun</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bouhss</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Diepeveen-de Bruin</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Nguyen-Disteche</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>de Kruijff</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Breukink</surname>
                                <given-names>E.</given-names>
                            </name>
                        </person-group>
                        <article-title>Identification of FtsW as a transporter of lipid-linked cell wall precursors
                            across the membrane
                        </article-title>
                        <source>Embo J.</source>
                        <year>2011</year>
                        <volume>30</volume>
                        <fpage>1425</fpage>
                        <lpage>1432</lpage>
                        <pub-id pub-id-type="doi">10.1038/emboj.2011.61</pub-id>
                        <pub-id pub-id-type="pmid">21386816</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3102273</pub-id>
                    </element-citation>
                </ref>
                <ref id="B45-pharmaceuticals-13-00392">
                    <label>45.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Ruiz</surname>
                                <given-names>N.</given-names>
                            </name>
                        </person-group>
                        <article-title>Bioinformatics identification of MurJ (MviN) as the peptidoglycan lipid II
                            flippase in Escherichia coli
                        </article-title>
                        <source>Proc. Natl. Acad. Sci. USA</source>
                        <year>2008</year>
                        <volume>105</volume>
                        <fpage>15553</fpage>
                        <lpage>15557</lpage>
                        <pub-id pub-id-type="doi">10.1073/pnas.0808352105</pub-id>
                        <pub-id pub-id-type="pmid">18832143</pub-id>
                        <pub-id pub-id-type="pmcid">PMC2563115</pub-id>
                    </element-citation>
                </ref>
                <ref id="B46-pharmaceuticals-13-00392">
                    <label>46.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Sham</surname>
                                <given-names>L.T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Butler</surname>
                                <given-names>E.K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lebar</surname>
                                <given-names>M.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kahne</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bernhardt</surname>
                                <given-names>T.G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ruiz</surname>
                                <given-names>N.</given-names>
                            </name>
                        </person-group>
                        <article-title>MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis
                        </article-title>
                        <source>Science</source>
                        <year>2014</year>
                        <volume>345</volume>
                        <fpage>220</fpage>
                        <lpage>222</lpage>
                        <pub-id pub-id-type="doi">10.1126/science.1254522</pub-id>
                        <pub-id pub-id-type="pmid">25013077</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4163187</pub-id>
                    </element-citation>
                </ref>
                <ref id="B47-pharmaceuticals-13-00392">
                    <label>47.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Ruiz</surname>
                                <given-names>N.</given-names>
                            </name>
                        </person-group>
                        <article-title>Lipid Flippases for Bacterial Peptidoglycan Biosynthesis</article-title>
                        <source>Lipid Insights</source>
                        <year>2015</year>
                        <volume>8</volume>
                        <fpage>21</fpage>
                        <lpage>31</lpage>
                        <pub-id pub-id-type="doi">10.4137/LPI.S31783</pub-id>
                        <pub-id pub-id-type="pmid">26792999</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4714577</pub-id>
                    </element-citation>
                </ref>
                <ref id="B48-pharmaceuticals-13-00392">
                    <label>48.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Teo</surname>
                                <given-names>A.C.K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Roper</surname>
                                <given-names>D.I.</given-names>
                            </name>
                        </person-group>
                        <article-title>Core Steps of Membrane-Bound Peptidoglycan Biosynthesis: Recent Advances, Insight
                            and Opportunities
                        </article-title>
                        <source>Antibiot. Basel</source>
                        <year>2015</year>
                        <volume>4</volume>
                        <fpage>495</fpage>
                        <lpage>520</lpage>
                        <pub-id pub-id-type="doi">10.3390/antibiotics4040495</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4790310</pub-id>
                        <pub-id pub-id-type="pmid">27025638</pub-id>
                    </element-citation>
                </ref>
                <ref id="B49-pharmaceuticals-13-00392">
                    <label>49.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Meeske</surname>
                                <given-names>A.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Sham</surname>
                                <given-names>L.T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kimsey</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Koo</surname>
                                <given-names>B.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gross</surname>
                                <given-names>C.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bernhardt</surname>
                                <given-names>T.G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Rudner</surname>
                                <given-names>D.Z.</given-names>
                            </name>
                        </person-group>
                        <article-title>MurJ and a novel lipid II flippase are required for cell wall biogenesis in
                            Bacillus subtilis
                        </article-title>
                        <source>Proc. Natl. Acad. Sci. USA</source>
                        <year>2015</year>
                        <volume>112</volume>
                        <fpage>6437</fpage>
                        <lpage>6442</lpage>
                        <pub-id pub-id-type="doi">10.1073/pnas.1504967112</pub-id>
                        <pub-id pub-id-type="pmid">25918422</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4443310</pub-id>
                    </element-citation>
                </ref>
                <ref id="B50-pharmaceuticals-13-00392">
                    <label>50.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Egan</surname>
                                <given-names>A.J.F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Errington</surname>
                                <given-names>J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vollmer</surname>
                                <given-names>W.</given-names>
                            </name>
                        </person-group>
                        <article-title>Regulation of peptidoglycan synthesis and remodelling</article-title>
                        <source>Nat. Rev. Microbiol.</source>
                        <year>2020</year>
                        <volume>18</volume>
                        <fpage>446</fpage>
                        <lpage>460</lpage>
                        <pub-id pub-id-type="doi">10.1038/s41579-020-0366-3</pub-id>
                        <pub-id pub-id-type="pmid">32424210</pub-id>
                    </element-citation>
                </ref>
                <ref id="B51-pharmaceuticals-13-00392">
                    <label>51.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Manat</surname>
                                <given-names>G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Roure</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Auger</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bouhss</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Barreteau</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mengin-Lecreulx</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Touzé</surname>
                                <given-names>T.</given-names>
                            </name>
                        </person-group>
                        <article-title>Deciphering the metabolism of undecaprenyl-phosphate: The bacterial cell-wall
                            unit carrier at the membrane frontier
                        </article-title>
                        <source>Microb. Drug Resist.</source>
                        <year>2014</year>
                        <volume>20</volume>
                        <fpage>199</fpage>
                        <lpage>214</lpage>
                        <pub-id pub-id-type="doi">10.1089/mdr.2014.0035</pub-id>
                        <pub-id pub-id-type="pmid">24799078</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4050452</pub-id>
                    </element-citation>
                </ref>
                <ref id="B52-pharmaceuticals-13-00392">
                    <label>52.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Lebar</surname>
                                <given-names>M.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>May</surname>
                                <given-names>J.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Meeske</surname>
                                <given-names>A.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Leiman</surname>
                                <given-names>S.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lupoli</surname>
                                <given-names>T.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Tsukamoto</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Losick</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Rudner</surname>
                                <given-names>D.Z.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walker</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kahne</surname>
                                <given-names>D.</given-names>
                            </name>
                        </person-group>
                        <article-title>Reconstitution of Peptidoglycan Cross-Linking Leads to Improved Fluorescent
                            Probes of Cell Wall Synthesis
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2014</year>
                        <volume>136</volume>
                        <fpage>10874</fpage>
                        <lpage>10877</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja505668f</pub-id>
                        <pub-id pub-id-type="pmid">25036369</pub-id>
                        <pub-id pub-id-type="pmcid">PMC4132960</pub-id>
                    </element-citation>
                </ref>
                <ref id="B53-pharmaceuticals-13-00392">
                    <label>53.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Travassos</surname>
                                <given-names>L.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Girardin</surname>
                                <given-names>S.E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Philpott</surname>
                                <given-names>D.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blanot</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Nahori</surname>
                                <given-names>M.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Werts</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boneca</surname>
                                <given-names>I.G.</given-names>
                            </name>
                        </person-group>
                        <article-title>Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan
                            recognition
                        </article-title>
                        <source>EMBO Rep.</source>
                        <year>2004</year>
                        <volume>5</volume>
                        <fpage>1000</fpage>
                        <lpage>1006</lpage>
                        <pub-id pub-id-type="doi">10.1038/sj.embor.7400248</pub-id>
                        <pub-id pub-id-type="pmid">15359270</pub-id>
                        <pub-id pub-id-type="pmcid">PMC1299148</pub-id>
                    </element-citation>
                </ref>
                <ref id="B54-pharmaceuticals-13-00392">
                    <label>54.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Wolf</surname>
                                <given-names>A.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Underhill</surname>
                                <given-names>D.M.</given-names>
                            </name>
                        </person-group>
                        <article-title>Peptidoglycan recognition by the innate immune system</article-title>
                        <source>Nat. Rev. Immunol.</source>
                        <year>2018</year>
                        <volume>18</volume>
                        <fpage>243</fpage>
                        <lpage>254</lpage>
                        <pub-id pub-id-type="doi">10.1038/nri.2017.136</pub-id>
                        <pub-id pub-id-type="pmid">29292393</pub-id>
                    </element-citation>
                </ref>
                <ref id="B55-pharmaceuticals-13-00392">
                    <label>55.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Inamura</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kusumoto</surname>
                                <given-names>S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthetic study of peptidoglycan partial structures. Synthesis of tetrasaccharide
                            and octasaccharide fragments
                        </article-title>
                        <source>Tetrahedron Lett.</source>
                        <year>2001</year>
                        <volume>42</volume>
                        <fpage>7613</fpage>
                        <lpage>7616</lpage>
                        <pub-id pub-id-type="doi">10.1016/S0040-4039(01)01619-7</pub-id>
                    </element-citation>
                </ref>
                <ref id="B56-pharmaceuticals-13-00392">
                    <label>56.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Kusumoto</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yamamoto</surname>
                                <given-names>K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Imoto</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inage</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Tsujimoto</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kotani</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shiba</surname>
                                <given-names>T.</given-names>
                            </name>
                        </person-group>
                        <article-title>Chemical synthesis and biological-activities of 2 disaccharide dipeptides
                            corresponding to the repeating units of bacterial peptidoglycan
                        </article-title>
                        <source>Bull. Chem. Soc. Jpn.</source>
                        <year>1986</year>
                        <volume>59</volume>
                        <fpage>1411</fpage>
                        <lpage>1417</lpage>
                        <pub-id pub-id-type="doi">10.1246/bcsj.59.1411</pub-id>
                    </element-citation>
                </ref>
                <ref id="B57-pharmaceuticals-13-00392">
                    <label>57.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Schwartz</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Markwalder</surname>
                                <given-names>J.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>Y.</given-names>
                            </name>
                        </person-group>
                        <article-title>Lipid II: Total synthesis of the bacterial cell wall precursor and utilization as
                            a substrate for glycosyltransfer and transpeptidation by penicillin binding protein (PBP) 1b
                            of Eschericia coli
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2001</year>
                        <volume>123</volume>
                        <fpage>11638</fpage>
                        <lpage>11643</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja0166848</pub-id>
                        <pub-id pub-id-type="pmid">11716719</pub-id>
                    </element-citation>
                </ref>
                <ref id="B58-pharmaceuticals-13-00392">
                    <label>58.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Saha</surname>
                                <given-names>S.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Van Nieuwenhze</surname>
                                <given-names>M.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hornback</surname>
                                <given-names>W.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Aikins</surname>
                                <given-names>J.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blaszczak</surname>
                                <given-names>L.C.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of an orthogonally protected precursor to the glycan repeating unit of
                            the bacterial cell wall
                        </article-title>
                        <source>Org. Lett.</source>
                        <year>2001</year>
                        <volume>3</volume>
                        <fpage>3575</fpage>
                        <lpage>3577</lpage>
                        <pub-id pub-id-type="doi">10.1021/ol016692t</pub-id>
                        <pub-id pub-id-type="pmid">11678712</pub-id>
                    </element-citation>
                </ref>
                <ref id="B59-pharmaceuticals-13-00392">
                    <label>59.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>VanNieuwenhze</surname>
                                <given-names>M.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mauldin</surname>
                                <given-names>S.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Zia-Ebrahimi</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Winger</surname>
                                <given-names>B.E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hornback</surname>
                                <given-names>W.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Saha</surname>
                                <given-names>S.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Aikins</surname>
                                <given-names>J.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Blaszczak</surname>
                                <given-names>L.C.</given-names>
                            </name>
                        </person-group>
                        <article-title>The first total synthesis of lipid II: The final monomeric intermediate in
                            bacterial cell wall biosynthesis
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2002</year>
                        <volume>124</volume>
                        <fpage>3656</fpage>
                        <lpage>3660</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja017386d</pub-id>
                        <pub-id pub-id-type="pmid">11929255</pub-id>
                    </element-citation>
                </ref>
                <ref id="B60-pharmaceuticals-13-00392">
                    <label>60.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Chowdhury</surname>
                                <given-names>A.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Siriwardena</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boons</surname>
                                <given-names>G.J.</given-names>
                            </name>
                        </person-group>
                        <article-title>A highly convergent approach for the synthesis of disaccharide repeating units of
                            peptidoglycan
                        </article-title>
                        <source>Tetrahedron Lett.</source>
                        <year>2002</year>
                        <volume>43</volume>
                        <fpage>7805</fpage>
                        <lpage>7807</lpage>
                        <pub-id pub-id-type="doi">10.1016/S0040-4039(02)01753-7</pub-id>
                    </element-citation>
                </ref>
                <ref id="B61-pharmaceuticals-13-00392">
                    <label>61.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Hesek</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lee</surname>
                                <given-names>M.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Morio</surname>
                                <given-names>K.I.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mobashery</surname>
                                <given-names>S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of a fragment of bacterial cell wall</article-title>
                        <source>J. Org. Chem.</source>
                        <year>2004</year>
                        <volume>69</volume>
                        <fpage>2137</fpage>
                        <lpage>2146</lpage>
                        <pub-id pub-id-type="doi">10.1021/jo035583k</pub-id>
                        <pub-id pub-id-type="pmid">15058963</pub-id>
                    </element-citation>
                </ref>
                <ref id="B62-pharmaceuticals-13-00392">
                    <label>62.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Inamura</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kawasaki</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shiokawa</surname>
                                <given-names>Z.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Woelk</surname>
                                <given-names>E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Heine</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lindner</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inohara</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kusumoto</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of peptidoglycan fragments and evaluation of their biological
                            activity
                        </article-title>
                        <source>Org. Biomol. Chem.</source>
                        <year>2006</year>
                        <volume>4</volume>
                        <fpage>232</fpage>
                        <lpage>242</lpage>
                        <pub-id pub-id-type="doi">10.1039/B511866B</pub-id>
                        <pub-id pub-id-type="pmid">16391765</pub-id>
                    </element-citation>
                </ref>
                <ref id="B63-pharmaceuticals-13-00392">
                    <label>63.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Zhang</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fechter</surname>
                                <given-names>E.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>T.S.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Barrett</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walker</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kahne</surname>
                                <given-names>D.E.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of heptaprenyl-lipid IV to analyze peptidoglycan glycosyltransferases
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2007</year>
                        <volume>129</volume>
                        <fpage>3080</fpage>
                        <pub-id pub-id-type="doi">10.1021/ja069060g</pub-id>
                        <pub-id pub-id-type="pmid">17323951</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3222299</pub-id>
                    </element-citation>
                </ref>
                <ref id="B64-pharmaceuticals-13-00392">
                    <label>64.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Ye</surname>
                                <given-names>X.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lo</surname>
                                <given-names>M.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Brunner</surname>
                                <given-names>L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walker</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kahne</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Walker</surname>
                                <given-names>S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Better substrates for bacterial transglycosylases</article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2001</year>
                        <volume>123</volume>
                        <fpage>3155</fpage>
                        <lpage>3156</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja010028q</pub-id>
                        <pub-id pub-id-type="pmid">11457035</pub-id>
                    </element-citation>
                </ref>
                <ref id="B65-pharmaceuticals-13-00392">
                    <label>65.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Konishi</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kubo</surname>
                                <given-names>O.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hasegawa</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inohara</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of crosslinked peptidoglycan fragments for investigation of their
                            immunobiological functions
                        </article-title>
                        <source>Tetrahedron Lett.</source>
                        <year>2009</year>
                        <volume>50</volume>
                        <fpage>3631</fpage>
                        <lpage>3634</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.tetlet.2009.03.081</pub-id>
                    </element-citation>
                </ref>
                <ref id="B66-pharmaceuticals-13-00392">
                    <label>66.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Uehara</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yang</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kusumoto</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shibata</surname>
                                <given-names>K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Sugawara</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Takada</surname>
                                <given-names>H.</given-names>
                            </name>
                        </person-group>
                        <article-title>Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in
                            combination with chemically synthesized Toll-like receptor agonists synergistically induced
                            production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human
                            monocytic cells in culture
                        </article-title>
                        <source>Cell. Microbiol.</source>
                        <year>2005</year>
                        <volume>7</volume>
                        <fpage>53</fpage>
                        <lpage>61</lpage>
                        <pub-id pub-id-type="doi">10.1111/j.1462-5822.2004.00433.x</pub-id>
                        <pub-id pub-id-type="pmid">15617523</pub-id>
                    </element-citation>
                </ref>
                <ref id="B67-pharmaceuticals-13-00392">
                    <label>67.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Huang</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hasegawa</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inohara</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Glycan Sequence-Dependent Nod2 Activation Investigated by Using a Chemically
                            Synthesized Bacterial Peptidoglycan Fragment Library
                        </article-title>
                        <source>Chembiochem</source>
                        <year>2013</year>
                        <volume>14</volume>
                        <fpage>482</fpage>
                        <lpage>488</lpage>
                        <pub-id pub-id-type="doi">10.1002/cbic.201200655</pub-id>
                        <pub-id pub-id-type="pmid">23362105</pub-id>
                    </element-citation>
                </ref>
                <ref id="B68-pharmaceuticals-13-00392">
                    <label>68.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pradipta</surname>
                                <given-names>A.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inohara</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Peptidoglycan as Nod1 ligand; fragment structures in the environment, chemical
                            synthesis, and their innate immunostimulation
                        </article-title>
                        <source>Nat. Prod. Rep.</source>
                        <year>2012</year>
                        <volume>29</volume>
                        <fpage>568</fpage>
                        <lpage>579</lpage>
                        <pub-id pub-id-type="doi">10.1039/c2np00091a</pub-id>
                        <pub-id pub-id-type="pmid">22370813</pub-id>
                    </element-citation>
                </ref>
                <ref id="B69-pharmaceuticals-13-00392">
                    <label>69.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inamura</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kawasaki</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shiokawa</surname>
                                <given-names>Z.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shimoyama</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hashimoto</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kusumoto</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Chemical synthesis of peptidoglycan fragments for elucidation of the
                            immunostimulating mechanism
                        </article-title>
                        <source>J. Endotoxin Res.</source>
                        <year>2007</year>
                        <volume>13</volume>
                        <fpage>189</fpage>
                        <lpage>196</lpage>
                        <pub-id pub-id-type="doi">10.1177/0968051907080739</pub-id>
                        <pub-id pub-id-type="pmid">17621561</pub-id>
                    </element-citation>
                </ref>
                <ref id="B70-pharmaceuticals-13-00392">
                    <label>70.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Enugala</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pires</surname>
                                <given-names>M.J.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of the NAG-NAM disaccharide via a versatile intermediate
                        </article-title>
                        <source>Carbohydr. Res.</source>
                        <year>2014</year>
                        <volume>384</volume>
                        <fpage>112</fpage>
                        <lpage>118</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.carres.2013.12.007</pub-id>
                        <pub-id pub-id-type="pmid">24374641</pub-id>
                    </element-citation>
                </ref>
                <ref id="B71-pharmaceuticals-13-00392">
                    <label>71.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>Q.Q.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Matsuo</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pradipta</surname>
                                <given-names>A.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Inohara</surname>
                                <given-names>N.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fujimoto</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Fukase</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of characteristic Mycobacterium peptidoglycan (PGN) fragments utilizing
                            with chemoenzymatic preparation of meso-diaminopimelic acid (DAP), and their modulation of
                            innate immune responses
                        </article-title>
                        <source>Org. Biomol. Chem.</source>
                        <year>2016</year>
                        <volume>14</volume>
                        <fpage>1013</fpage>
                        <lpage>1023</lpage>
                        <pub-id pub-id-type="doi">10.1039/C5OB02145F</pub-id>
                        <pub-id pub-id-type="pmid">26631868</pub-id>
                    </element-citation>
                </ref>
                <ref id="B72-pharmaceuticals-13-00392">
                    <label>72.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Enugala</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Synthesis of a 3-hydroxyl-free N-acetyl glucosamine disaccharide</article-title>
                        <source>Arkivoc</source>
                        <year>2012</year>
                        <fpage>90</fpage>
                        <lpage>100</lpage>
                        <pub-id pub-id-type="doi">10.3998/ark.5550190.0013.608</pub-id>
                    </element-citation>
                </ref>
                <ref id="B73-pharmaceuticals-13-00392">
                    <label>73.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Marqvorsen</surname>
                                <given-names>M.H.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pedersen</surname>
                                <given-names>M.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Rasmussen</surname>
                                <given-names>M.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kristensen</surname>
                                <given-names>S.K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Dahl-Lassen</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Jensen</surname>
                                <given-names>H.H.</given-names>
                            </name>
                        </person-group>
                        <article-title>Why Is Direct Glycosylation with N-Acetylglucosamine Donors Such a Poor Reaction
                            and What Can Be Done about It?
                        </article-title>
                        <source>J. Org. Chem.</source>
                        <year>2017</year>
                        <volume>82</volume>
                        <fpage>143</fpage>
                        <lpage>156</lpage>
                        <pub-id pub-id-type="doi">10.1021/acs.joc.6b02305</pub-id>
                        <pub-id pub-id-type="pmid">28001415</pub-id>
                    </element-citation>
                </ref>
                <ref id="B74-pharmaceuticals-13-00392">
                    <label>74.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Xolin</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Stevenin</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pucheault</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Norsikian</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boyer</surname>
                                <given-names>F.D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Beau</surname>
                                <given-names>J.M.</given-names>
                            </name>
                        </person-group>
                        <article-title>Glycosylation with N-acetyl glycosamine donors using catalytic iron(III)
                            triflate: From microwave batch chemistry to a scalable continuous-flow process
                        </article-title>
                        <source>Org. Chem. Front.</source>
                        <year>2014</year>
                        <volume>1</volume>
                        <fpage>992</fpage>
                        <lpage>1000</lpage>
                        <pub-id pub-id-type="doi">10.1039/C4QO00183D</pub-id>
                    </element-citation>
                </ref>
                <ref id="B75-pharmaceuticals-13-00392">
                    <label>75.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Enugala</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Carvalho</surname>
                                <given-names>L.C.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>Towards Glucosamine Building Blocks: Regioselective One-Pot Protection and
                            Deallylation Procedures
                        </article-title>
                        <source>Synlett</source>
                        <year>2010</year>
                        <fpage>2711</fpage>
                        <lpage>2716</lpage>
                        <pub-id pub-id-type="doi">10.1055/s-0030-1259001</pub-id>
                    </element-citation>
                </ref>
                <ref id="B76-pharmaceuticals-13-00392">
                    <label>76.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Carvalho</surname>
                                <given-names>L.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Corvo</surname>
                                <given-names>M.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Enugala</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Cabrita</surname>
                                <given-names>E.J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Application of HR-MAS NMR in the solid-phase synthesis of a glycopeptide using
                            Sieber amide resin
                        </article-title>
                        <source>Magn. Reson. Chem.</source>
                        <year>2010</year>
                        <volume>48</volume>
                        <fpage>323</fpage>
                        <lpage>330</lpage>
                        <pub-id pub-id-type="doi">10.1002/mrc.2583</pub-id>
                        <pub-id pub-id-type="pmid">20222070</pub-id>
                    </element-citation>
                </ref>
                <ref id="B77-pharmaceuticals-13-00392">
                    <label>77.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Kulkarni</surname>
                                <given-names>S.S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wang</surname>
                                <given-names>C.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Sabbavarapu</surname>
                                <given-names>N.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Podilapu</surname>
                                <given-names>A.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Liao</surname>
                                <given-names>P.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hung</surname>
                                <given-names>S.C.</given-names>
                            </name>
                        </person-group>
                        <article-title>“One-Pot” Protection, Glycosylation, and Protection-Glycosylation Strategies of
                            Carbohydrates
                        </article-title>
                        <source>Chem. Rev.</source>
                        <year>2018</year>
                        <volume>118</volume>
                        <fpage>8025</fpage>
                        <lpage>8104</lpage>
                        <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00036</pub-id>
                        <pub-id pub-id-type="pmid">29870239</pub-id>
                    </element-citation>
                </ref>
                <ref id="B78-pharmaceuticals-13-00392">
                    <label>78.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Ito</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kanie</surname>
                                <given-names>O.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ogawa</surname>
                                <given-names>T.</given-names>
                            </name>
                        </person-group>
                        <article-title>Orthogonal glycosylation strategy for rapid assembly of oligosaccharides on a
                            polymer support
                        </article-title>
                        <source>Angew. Chem. Int. Ed. Engl.</source>
                        <year>1996</year>
                        <volume>35</volume>
                        <fpage>2510</fpage>
                        <lpage>2512</lpage>
                        <pub-id pub-id-type="doi">10.1002/anie.199625101</pub-id>
                    </element-citation>
                </ref>
                <ref id="B79-pharmaceuticals-13-00392">
                    <label>79.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Carvalho</surname>
                                <given-names>L.C.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Queda</surname>
                                <given-names>F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Almeida</surname>
                                <given-names>C.V.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Filipe</surname>
                                <given-names>S.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>From a Natural Polymer to Relevant NAG-NAM Precursors</article-title>
                        <source>Asian J. Org. Chem.</source>
                        <year>2018</year>
                        <volume>7</volume>
                        <fpage>2544</fpage>
                        <lpage>2551</lpage>
                        <pub-id pub-id-type="doi">10.1002/ajoc.201800592</pub-id>
                    </element-citation>
                </ref>
                <ref id="B80-pharmaceuticals-13-00392">
                    <label>80.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Nishimura</surname>
                                <given-names>S.I.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kuzuhara</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Takiguchi</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shimahara</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Peracetylated chitobiose-preparation by specific degradations of chitin, and
                            chemical manipulations
                        </article-title>
                        <source>Carbohydr. Res.</source>
                        <year>1989</year>
                        <volume>194</volume>
                        <fpage>223</fpage>
                        <lpage>231</lpage>
                        <pub-id pub-id-type="doi">10.1016/0008-6215(89)85021-9</pub-id>
                    </element-citation>
                </ref>
                <ref id="B81-pharmaceuticals-13-00392">
                    <label>81.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Chang</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yeager</surname>
                                <given-names>A.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Finney</surname>
                                <given-names>N.S.</given-names>
                            </name>
                        </person-group>
                        <article-title>Probing the mechanism of a fungal glycosyltransferase essential for cell wall
                            biosynthesis. UDP-chitobiose is not a substrate for chitin synthase
                        </article-title>
                        <source>Org. Biomol. Chem.</source>
                        <year>2003</year>
                        <volume>1</volume>
                        <fpage>39</fpage>
                        <lpage>41</lpage>
                        <pub-id pub-id-type="doi">10.1039/b208953j</pub-id>
                        <pub-id pub-id-type="pmid">12929388</pub-id>
                    </element-citation>
                </ref>
                <ref id="B82-pharmaceuticals-13-00392">
                    <label>82.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Despras</surname>
                                <given-names>G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Alix</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Urban</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Vauzeilles</surname>
                                <given-names>B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Beau</surname>
                                <given-names>J.M.</given-names>
                            </name>
                        </person-group>
                        <article-title>From Chitin to Bioactive Chitooligosaccharides and Conjugates: Access to
                            Lipochitooligosaccharides and the TMG-chitotriomycin
                        </article-title>
                        <source>Angew. Chem. Int. Ed.</source>
                        <year>2014</year>
                        <volume>53</volume>
                        <fpage>11912</fpage>
                        <lpage>11916</lpage>
                        <pub-id pub-id-type="doi">10.1002/anie.201406802</pub-id>
                        <pub-id pub-id-type="pmid">25212734</pub-id>
                    </element-citation>
                </ref>
                <ref id="B83-pharmaceuticals-13-00392">
                    <label>83.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Queda</surname>
                                <given-names>F.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Covas</surname>
                                <given-names>G.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Silva</surname>
                                <given-names>T.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Santos</surname>
                                <given-names>C.A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Bronze</surname>
                                <given-names>M.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Canada</surname>
                                <given-names>F.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Corvo</surname>
                                <given-names>M.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Filipe</surname>
                                <given-names>S.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Marques</surname>
                                <given-names>M.M.B.</given-names>
                            </name>
                        </person-group>
                        <article-title>A top-down chemo-enzymatic approach towards N-acetylglucosamine-N-acetylmuramic
                            oligosaccharides: Chitosan as a reliable template
                        </article-title>
                        <source>Carbohydr. Polym.</source>
                        <year>2019</year>
                        <volume>224</volume>
                        <pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115133</pub-id>
                        <pub-id pub-id-type="pmid">31472863</pub-id>
                    </element-citation>
                </ref>
                <ref id="B84-pharmaceuticals-13-00392">
                    <label>84.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Goodman</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pollock</surname>
                                <given-names>J.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Iacono</surname>
                                <given-names>V.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wong</surname>
                                <given-names>W.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shockman</surname>
                                <given-names>G.D.</given-names>
                            </name>
                        </person-group>
                        <article-title>Peptidoglycan loss during hen egg-white lysozyme-inorganic salt lysis of
                            streptococcus-mutans
                        </article-title>
                        <source>J. Bacteriol.</source>
                        <year>1981</year>
                        <volume>146</volume>
                        <fpage>755</fpage>
                        <lpage>763</lpage>
                        <pub-id pub-id-type="doi">10.1128/JB.146.2.755-763.1981</pub-id>
                        <pub-id pub-id-type="pmid">7217016</pub-id>
                        <pub-id pub-id-type="pmcid">PMC217022</pub-id>
                    </element-citation>
                </ref>
                <ref id="B85-pharmaceuticals-13-00392">
                    <label>85.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Kurita</surname>
                                <given-names>K.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ikeda</surname>
                                <given-names>H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Yoshida</surname>
                                <given-names>Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Shimojoh</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Harata</surname>
                                <given-names>M.</given-names>
                            </name>
                        </person-group>
                        <article-title>Chemoselective protection of the amino groups of chitosan by controlled
                            phthaloylation: Facile preparation of a precursor useful for chemical modifications
                        </article-title>
                        <source>Biomacromolecules</source>
                        <year>2002</year>
                        <volume>3</volume>
                        <fpage>1</fpage>
                        <lpage>4</lpage>
                        <pub-id pub-id-type="doi">10.1021/bm0101163</pub-id>
                        <pub-id pub-id-type="pmid">11866549</pub-id>
                    </element-citation>
                </ref>
                <ref id="B86-pharmaceuticals-13-00392">
                    <label>86.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Binette</surname>
                                <given-names>A.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Gagnon</surname>
                                <given-names>J.</given-names>
                            </name>
                        </person-group>
                        <article-title>Regioselective silylation of N-phthaloylchitosan with TBDMS and TBDPS groups
                        </article-title>
                        <source>Biomacromolecules</source>
                        <year>2007</year>
                        <volume>8</volume>
                        <fpage>1812</fpage>
                        <lpage>1815</lpage>
                        <pub-id pub-id-type="doi">10.1021/bm0610976</pub-id>
                        <pub-id pub-id-type="pmid">17487971</pub-id>
                    </element-citation>
                </ref>
                <ref id="B87-pharmaceuticals-13-00392">
                    <label>87.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Lee</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Artola-Recolons</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Carrasco-Lopez</surname>
                                <given-names>C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Martinez-Caballero</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hesek</surname>
                                <given-names>D.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Spink</surname>
                                <given-names>E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Lastochkin</surname>
                                <given-names>E.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Zhang</surname>
                                <given-names>W.L.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Hellman</surname>
                                <given-names>L.M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Boggess</surname>
                                <given-names>B.</given-names>
                            </name>
                            <etal/>
                        </person-group>
                        <article-title>Cell-Wall Remodeling by the Zinc-Protease AmpDh3 from Pseudomonas aeruginosa
                        </article-title>
                        <source>J. Am. Chem. Soc.</source>
                        <year>2013</year>
                        <volume>135</volume>
                        <fpage>12604</fpage>
                        <lpage>12607</lpage>
                        <pub-id pub-id-type="doi">10.1021/ja407445x</pub-id>
                        <pub-id pub-id-type="pmid">23931161</pub-id>
                        <pub-id pub-id-type="pmcid">PMC3842012</pub-id>
                    </element-citation>
                </ref>
                <ref id="B88-pharmaceuticals-13-00392">
                    <label>88.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Vocadlo</surname>
                                <given-names>D.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Davies</surname>
                                <given-names>G.J.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Laine</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Withers</surname>
                                <given-names>S.G.</given-names>
                            </name>
                        </person-group>
                        <article-title>Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate
                        </article-title>
                        <source>Nature</source>
                        <year>2001</year>
                        <volume>412</volume>
                        <fpage>835</fpage>
                        <lpage>838</lpage>
                        <pub-id pub-id-type="doi">10.1038/35090602</pub-id>
                        <pub-id pub-id-type="pmid">11518970</pub-id>
                    </element-citation>
                </ref>
                <ref id="B89-pharmaceuticals-13-00392">
                    <label>89.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Maeda</surname>
                                <given-names>R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Matsumoto</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Kondo</surname>
                                <given-names>K.</given-names>
                            </name>
                        </person-group>
                        <article-title>Enzymatic hydrolysis reaction of water-soluble chitin derivatives with egg white
                            lysozyme
                        </article-title>
                        <source>J. Ferment. Bioeng.</source>
                        <year>1997</year>
                        <volume>84</volume>
                        <fpage>478</fpage>
                        <lpage>479</lpage>
                        <pub-id pub-id-type="doi">10.1016/S0922-338X(97)82012-0</pub-id>
                    </element-citation>
                </ref>
                <ref id="B90-pharmaceuticals-13-00392">
                    <label>90.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Amano</surname>
                                <given-names>K.I.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Ito</surname>
                                <given-names>E.</given-names>
                            </name>
                        </person-group>
                        <article-title>Action of lysozyme on partially deacetylated chitin</article-title>
                        <source>Eur. J. Biochem.</source>
                        <year>1978</year>
                        <volume>85</volume>
                        <fpage>97</fpage>
                        <lpage>104</lpage>
                        <pub-id pub-id-type="doi">10.1111/j.1432-1033.1978.tb12216.x</pub-id>
                        <pub-id pub-id-type="pmid">639827</pub-id>
                    </element-citation>
                </ref>
                <ref id="B91-pharmaceuticals-13-00392">
                    <label>91.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Raymond</surname>
                                <given-names>J.B.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Price</surname>
                                <given-names>N.P.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Pavelka</surname>
                                <given-names>M.S.</given-names>
                            </name>
                        </person-group>
                        <article-title>A method for the enzymatic synthesis and HPLC purification of the peptidoglycan
                            precursor UDP-N-acetylmuramic acid
                        </article-title>
                        <source>Fems Microbiol. Lett.</source>
                        <year>2003</year>
                        <volume>229</volume>
                        <fpage>83</fpage>
                        <lpage>89</lpage>
                        <pub-id pub-id-type="doi">10.1016/S0378-1097(03)00793-6</pub-id>
                        <pub-id pub-id-type="pmid">14659546</pub-id>
                    </element-citation>
                </ref>
                <ref id="B92-pharmaceuticals-13-00392">
                    <label>92.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Huang</surname>
                                <given-names>L.Y.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Huang</surname>
                                <given-names>S.H.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Chang</surname>
                                <given-names>Y.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Cheng</surname>
                                <given-names>W.C.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Cheng</surname>
                                <given-names>T.J.R.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Wong</surname>
                                <given-names>C.H.</given-names>
                            </name>
                        </person-group>
                        <article-title>Enzymatic Synthesis of Lipid II and Analogues</article-title>
                        <source>Angew. Chem. Int. Ed.</source>
                        <year>2014</year>
                        <volume>53</volume>
                        <fpage>8060</fpage>
                        <lpage>8065</lpage>
                        <pub-id pub-id-type="doi">10.1002/anie.201402313</pub-id>
                        <pub-id pub-id-type="pmid">24990652</pub-id>
                    </element-citation>
                </ref>
                <ref id="B93-pharmaceuticals-13-00392">
                    <label>93.</label>
                    <element-citation publication-type="journal">
                        <person-group person-group-type="author">
                            <name name-style="western">
                                <surname>Unsleber</surname>
                                <given-names>S.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Borisova</surname>
                                <given-names>M.</given-names>
                            </name>
                            <name name-style="western">
                                <surname>Mayer</surname>
                                <given-names>C.</given-names>
                            </name>
                        </person-group>
                        <article-title>Enzymatic synthesis and semi-preparative isolation of N-acetylmuramic acid
                            6-phosphate
                        </article-title>
                        <source>Carbohydr. Res.</source>
                        <year>2017</year>
                        <volume>445</volume>
                        <fpage>98</fpage>
                        <lpage>103</lpage>
                        <pub-id pub-id-type="doi">10.1016/j.carres.2017.04.005</pub-id>
                        <pub-id pub-id-type="pmid">28505548</pub-id>
                    </element-citation>
                </ref>
            </ref-list>
            <sec sec-type="display-objects">
                <title>Figures and Schemes</title>
                <fig id="pharmaceuticals-13-00392-f001" orientation="portrait" position="float">
                    <label>Figure 1</label>
                    <caption>
                        <p>Representation of the monomeric muropeptides frequently found in the peptidoglycan (PGN) of
                            different bacteria. (<bold>a</bold>) the structure of the <italic toggle="yes">
                                Staphylococcus aureus
                            </italic> PGN (a Lys-type PGN) unit is presented. <italic toggle="yes">N</italic>-acetylglucosamine
                            (NAG)–<italic toggle="yes">N</italic>-acetylmuramic (NAM) disaccharide units (red) are
                            linked to each other via NAG-(β-1,4)–NAM linkage. Stem peptides (black), of which the
                            composition is specific for each bacteria species, are attached to the <sc>d</sc>-lactyl
                            (Lac – highlighted in the green circle) moiety of each NAM. The sequence of the peptide stem
                            attached to the lactyl carboxylate of NAM is <sc>l-</sc>Ala-<sc>d</sc>-iGln-<sc>
                                l</sc>-Lys-<sc>d</sc>-Ala-<sc>d</sc>-Ala. (<bold>b</bold>) the structure of a
                            muropeptide of Gram-positive <italic toggle="yes">Mycobacterium</italic> spp., with an
                            L-Ala-D-<italic toggle="yes">i</italic>Gln-<italic toggle="yes">meso</italic>-DAP-<sc>d</sc>-Ala-<sc>
                                d</sc>-Ala stem peptide sequence. (<bold>c</bold>) a representative muropeptide of the
                            Gram-negative bacterium <italic toggle="yes">Escherichia coli</italic>.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-g001.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-f002" orientation="portrait" position="float">
                    <label>Figure 2</label>
                    <caption>
                        <p>Schematic representation of PGN biosynthesis in Gram-negative bacteria: (<bold>1</bold>)
                            synthesis of a PG precursor in the cytoplasm; (<bold>2</bold>) synthesis of lipid-linked
                            precursors at the inner leaflet of the cytoplasmatic membrane; (<bold>3</bold>) flipping to
                            the outer leaflet of the cytoplasmatic membrane and incorporation of the precursor into
                            nascent PGN by transglycosylation (TG) and transpeptidation (TP) reactions. Enzymes shown in
                            blue synthesize substrates added on the depicted reaction: Alr racemases convert <sc>l</sc>-Ala
                            to <sc>d</sc>-Ala and Ddl ligases form the <sc>d</sc>-Ala-<sc>d</sc>-Ala dipeptide.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-g002.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch001" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch001_Scheme 1</object-id>
                    <label>Scheme 1</label>
                    <caption>
                        <p>Synthesis of PGN fragment <bold>9</bold> reported by Fukase [<xref
                                rid="B55-pharmaceuticals-13-00392" ref-type="bibr">55</xref>]. (<bold>a</bold>) (i)
                            AllocCl, NaHCO<sub>3</sub>, H<sub>2</sub>O; (ii) AllylOH, DOWEX 50W X8 200–400 mesh, 80 °C;
                            (iii) PhCH(OMe)<sub>2</sub>, <italic toggle="yes">p</italic>-TsOH, 57%; (<bold>b</bold>) NaH
                            then trifluoromethanesulfonyl-<sc>l</sc>-(<italic toggle="yes">S</italic>)-2-propionic acid
                            benzyl ester, 98%; (<bold>c</bold>) Pd(PPh<sub>3</sub>)<sub>4</sub>, AcOH, DCM, then TrocCl,
                            58%; (<bold>d</bold>) Me<sub>3</sub>N·BH<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, ACN,
                            87%; (<bold>e</bold>) BnBr, AgO, DCM, 87%; (<bold>f</bold>) Ir complex, H<sub>2</sub>, THF,
                            then I<sub>2</sub>, H<sub>2</sub>O, 99%; (<bold>g</bold>) CCl<sub>3</sub>CN, Cs<sub>2</sub>CO<sub>
                                3</sub>, DCM, quantitative; (<bold>h</bold>) TMSOTf (0.1 equiv.), MS 4 Å, DCM, −15 °C,
                            88%; (<bold>i</bold>) Me<sub>3</sub>N·BH<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, ACN,
                            52%; (<bold>j</bold>) Ir complex, H<sub>2</sub>, THF, then I<sub>2</sub>, H<sub>2</sub>O,
                            91%; (<bold>k</bold>) CCl<sub>3</sub>CN, Cs2CO3, DCM, 85%; (<bold>l</bold>) TMSOTf (0.1
                            equiv.), MS 4 Å, DCM, −15 °C, 79%; (<bold>m</bold>) Me<sub>3</sub>N·BH<sub>3</sub>, BF<sub>
                                3</sub>·Et<sub>2</sub>O, ACN, 60%; (<bold>n</bold>) Ir complex, H<sub>2</sub>, THF, then
                            I<sub>2</sub>, H<sub>2</sub>O, 81%; (<bold>o</bold>) CCl<sub>3</sub>CN, Cs<sub>
                                2</sub>CO<sub>3</sub>, DCM, 83%; (<bold>p</bold>) TMSOTf (0.1 equiv.), MS 4 Å, DCM, −15
                            °C, 70%; (<bold>o</bold>) Zn–Cu, AcOH, then Ac<sub>2</sub>O, Py, 82%; (<bold>r</bold>) 1 M
                            NaOMe, THF, H<sub>2</sub>O: LiOH, dioxane, THF, H<sub>2</sub>O, 97%; (<bold>s</bold>) HCl·H-<sc>
                                l</sc>-Ala-<sc>d</sc>-Glu(OBn)-NH<sub>2</sub>, WSCI·HCl, HOBt, TEA, DCM, 31%; (t) Pd(OH)<sub>
                                2</sub>, AcOH, H<sub>2</sub> (10 atm), 48%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch001.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch002" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch002_Scheme 2</object-id>
                    <label>Scheme 2</label>
                    <caption>
                        <p>Synthesis of the Lipid II unit <bold>16</bold> (undecaprenyl phosphate, highlighted in blue)
                            reported by Wang [<xref rid="B57-pharmaceuticals-13-00392" ref-type="bibr">57</xref>].
                            (<bold>a</bold>) HAlaOTMSE, DIEA, HOBt, PyBOP, 1:1 THF:DCM, r.t. (room temperature), 2 h,
                            81%. (<bold>b</bold>) Catalyst TsOH, MeOH, 75 °C, 30 min, 89%. (<bold>c</bold>) Pyridine, 1
                            equiv. of AcCl, −30 °C, 15 min, then warm to r.t., 80%. (<bold>d</bold>) AgOTf (3 equiv.),
                            donor (2 equiv.), MS 4 Å, DCM, −40 °C, drybox, 3 h, then overnight, 60%. (<bold>e</bold>)
                            Amino-modified resin, MS 4 Å, butanol, 85 °C, 24 h, then pyridine, Ac<sub>2</sub>O, r.t.,
                            overnight, 53%. (<bold>f</bold>) 10%Pd/C, H<sub>2</sub>, MeOH, 1 h, 93%. (<bold>g</bold>)
                            Tetrazole, (BnO)<sub>2</sub>PN(i-Pr)<sub>2</sub>, DCM, −30 °C to r.t., 1 h, then <italic
                                    toggle="yes">m</italic>-CPBA, −40 °C to r.t., 1 h, 55%. (<bold>h</bold>) TBAF, THF,
                            r.t., 45 min, 87%. (<bold>i</bold>) H-γ-<sc>d</sc>-Glu(OTMSE)-Lys(TEOC)-<sc>d</sc>-Ala-<sc>
                                d</sc>-AlaOTMSE, DIEA, HOBt, PyBOP, 1:1 THF:DCM, r.t., 2 h, 61%. (<bold>j</bold>)
                            10%Pd/C, H<sub>2</sub>, MeOH, 1 h, 100%. (<bold>k</bold>) CDI, dry DMF, r.t., 4 h, then
                            MeOH, then undecaprenyl phosphate, r.t., 48 h, 39%. (<bold>l</bold>) TBAF, DMF, r.t., 24 h,
                            then 3% NaOMe, MeOH, 0 °C, 1 h, 35%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch002.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch003" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch003_Scheme 3</object-id>
                    <label>Scheme 3</label>
                    <caption>
                        <p>Synthesis of the Lipid II unit <bold>16</bold> reported by Blaszczak [<xref
                                rid="B58-pharmaceuticals-13-00392" ref-type="bibr">58</xref>,<xref
                                rid="B59-pharmaceuticals-13-00392" ref-type="bibr">59</xref>]. (<bold>a</bold>) <italic
                                toggle="yes">N</italic>-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, DCM, 2
                            h, 95%; (<bold>b</bold>) Et<sub>3</sub>SiH (3 equiv.), TFA (6 equiv.), DCM, 0 °C, 5 h, 61%;
                            (<bold>c</bold>) AgOTf (3 equiv.), donor (3 equiv.), MS 4 Å (5.5 wt equiv.), DCM, 25 °C, 20
                            h 84%; (<bold>d</bold>) (1) anhydrous ZnCl<sub>2</sub>,Ac<sub>2</sub>O/AcOH (2:1), 25 °C, 20
                            h; (2) Zn dust (20 reducing equiv.), 25 °C, 4 h, 67%. (<bold>e</bold>) H<sub>2</sub>, Pd/C,
                            MeOH/THF, 94% yield; (<bold>f</bold>) (1) dibenzyl-<italic toggle="yes">N,N</italic>-diethylphosphoramidite,
                            1H-tetrazole, DCM; (2) 30% H<sub>2</sub>O<sub>2</sub>, THF, −78 °C to room temperature, 78%
                            yield; (<bold>g</bold>) (1) DBU, DCM; (2) EDCI, NHS, DMF, then peptide and iPr<sub>2</sub>NEt,
                            46% yield; (<bold>h</bold>) H<sub>2</sub>, Pd/C, MeOH, then pyridine, 91% yield; (<bold>
                                i</bold>) (1) CDI/DMF/THF; (2) undecaprenyl mono-phosphate (bis-amonium salt); (<bold>
                                j</bold>) NaOH/H<sub>2</sub>O/1,4-dioxane, 24% overall yield from <bold>10</bold>.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch003.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch004" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch004_Scheme 4</object-id>
                    <label>Scheme 4</label>
                    <caption>
                        <p>Synthesis of the disaccharides <bold>26</bold> and <bold>27</bold>—precursors of NAM-NAG and
                            NAG-NAM reported by Boons [<xref rid="B60-pharmaceuticals-13-00392" ref-type="bibr">
                                60</xref>]. (<bold>a</bold>) TBDMSOTf, 2,6-lutidine, DCM, 96%; (<bold>b</bold>) PMBCl,
                            NaH, TBAI, THF, reflux, 84%; (<bold>c</bold>) Me<sub>3</sub>N·BH<sub>3</sub>, AlCl<sub>
                                3</sub>, THF, 72%; (<bold>d</bold>) HO(CH<sub>2</sub>)<sub>3</sub>N<sub>3</sub>, NIS,
                            TMSOTf, 67%; (<bold>e</bold>) NIS, TMSOTf, 62%; (<bold>f</bold>) H<sub>2</sub>N(CH<sub>
                                2</sub>)<sub>2</sub>NH<sub>2</sub>, EtOH then Ac<sub>2</sub>O, MeOH, 70%; (<bold>
                                g</bold>) Bu<sub>4</sub>NF, THF, 75%; (<bold>h</bold>) NaH, (<italic toggle="yes">
                                S</italic>)-2-chloropropionic acid, dioxane, <bold>14</bold> (76%) and <bold>15</bold> (66%);
                            (<bold>i</bold>) DDQ, DCM, H<sub>2</sub>O, 79%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch004.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch005" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch005_Scheme 5</object-id>
                    <label>Scheme 5</label>
                    <caption>
                        <p>Synthesis of the tetrasaccharide with pentapeptides attached to NAM units, <bold>33</bold>,
                            reported by Mobashery [<xref rid="B61-pharmaceuticals-13-00392" ref-type="bibr">61</xref>].
                            (<bold>a</bold>) TfOH, 71%. (<bold>b</bold>) (1) NaOMe, Amberlite IR-120 (H+), (2)
                            benzaldehyde dimethylacetal, <italic toggle="yes">p</italic>-TsOH, 60% in two steps; (<bold>
                                c</bold>) Ac<sub>2</sub>O, 85%; (<bold>d</bold>) <italic toggle="yes">n</italic>-Bu<sub>
                                4</sub>NF, 75%; (<bold>e</bold>) Cl<sub>3</sub>CCN, DBU; (<bold>f</bold>) acceptor A,
                            TfOH, 55% in two steps; (<bold>g</bold>) BH<sub>3</sub>.NMe<sub>3</sub>, BF<sub>
                                3</sub>.OEt<sub>2</sub>, 62%; (<bold>h</bold>) donor B, TfOH, 68%; (<bold>i</bold>) (1)
                            NaOH, dioxane/water (4:1); HCl, pH 3.0; (2) Ac<sub>2</sub>O, 48% in two steps; (<bold>
                                j</bold>) NaOMe, 74%; (<bold>k</bold>) NaH, (<italic toggle="yes">S</italic>)-2-chloropropionic
                            acid, 46%; (m) 4-nitrophenyl trifluoroacetate, pyridine; peptide (prepared as CF<sub>3</sub>CO<sub>
                                2</sub>H salt), 41%; (<bold>l</bold>) 60% AcOH; H<sub>2</sub>, Pd/C, 76%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch005.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch006" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch006_Scheme 6</object-id>
                    <label>Scheme 6</label>
                    <caption>
                        <p>Synthesis of the heptaprenyl—Lipid IV <bold>43b</bold> reported by Walker [<xref
                                rid="B63-pharmaceuticals-13-00392" ref-type="bibr">63</xref>]. (<bold>a</bold>) Bu<sub>
                            2</sub>SnO, toluene, reflux, then Bu<sub>4</sub>NI, BnBr, reflux, 51%; (<bold>b</bold>)
                            TBSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 91%; (<bold>c</bold>) <italic
                                    toggle="yes">m</italic>CPBA, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to −60 °C, 93%;
                            (<bold>d</bold>) (1) (Bu<sub>3</sub>Sn)<sub>2</sub>O, MeOH, reflux; (2) Bu<sub>4</sub>NI,
                            BnBr, toluene, 91 °C, 75%; (<bold>e</bold>) <italic toggle="yes">m</italic>CPBA, CH<sub>
                                2</sub>Cl<sub>2</sub>, −78 °C to −60 °C, 91%; (<bold>f</bold>) Tf<sub>2</sub>O, DTBMP,
                            ADMB, MS 4Å, CH<sub>2</sub>Cl<sub>2</sub>, −60 °C to −40 °C, 58%; (<bold>g</bold>) Tf<sub>
                                2</sub>O, DTBMP, ADMB, MS 4Å, CH<sub>2</sub>Cl<sub>2</sub>, −60 °C to −30 °C, 75%;
                            (<bold>h</bold>) <italic toggle="yes">m</italic>CPBA, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C
                            to −60 °C, 86%; (<bold>i</bold>) Tf<sub>2</sub>O, DTBMP, ADMB, MS 4Å, CH<sub>2</sub>Cl<sub>
                                2</sub>, −40 °C, 77%; (<bold>j</bold>) (NH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>,
                            THF/CH<sub>3</sub>CN/EtOH (1:2:1), 60 °C; (<bold>k</bold>) Ac<sub>2</sub>O, MeOH/H<sub>
                                2</sub>O (5:1), r.t., 75% two steps; (<bold>l</bold>) NaH, <italic toggle="yes">
                                S</italic>-(−)-2-bromo-propionic acid, THF, 0 °C to r.t.; (<bold>m</bold>) TMSCHN<sub>
                                2</sub>, benzene/MeOH (3:1), 0 °C, 70% two steps; (<bold>n</bold>) NIS, CH<sub>3</sub>CN/H<sub>
                                2</sub>O (5:1), r.t., 75%; o) 1<italic toggle="yes">H</italic>-tetrazole, (<italic
                                    toggle="yes">i</italic>-Pr)<sub>2</sub>NP(OBn)<sub>2</sub>, CH<sub>2</sub>Cl<sub>
                                2</sub>, −40 to −20 °C; (<bold>p</bold>) <italic toggle="yes">m</italic>CPBA, CH<sub>
                                2</sub>Cl<sub>2</sub>, −40 °C to r.t., 84% two steps; (<bold>q</bold>) TBAF, THF, 0 °C
                            to r.t.; (<bold>r</bold>) 1.3 M KOH, THF/H<sub>2</sub>O (10:1), r.t., 64% two steps; (<bold>
                                s</bold>) HATU, DIEA, DMF, r.t., 60%; (<bold>t</bold>) Pd(OH)<sub>2</sub>/C, H<sub>
                                2</sub>, 44%; (<bold>u</bold>) ammonium heptaprenyl phosphate, 1,1′-carbonyl
                            diimidazole, THF, r.t., then <bold>30</bold>, SnCl<sub>2</sub>, DMF, r.t., 50%; (<bold>
                                v</bold>) TBAF, DMF, r.t., 69%; (<bold>w</bold>) (CH<sub>3</sub>[14]CO)<sub>2</sub>O,
                            toluene/16 mM NaOH in MeOH (1:1), sonication, 37 °C, 50%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch006.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch007" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch007_Scheme 7</object-id>
                    <label>Scheme 7</label>
                    <caption>
                        <p>Synthesis of cross-linked PGN fragment <bold>46</bold> reported by Fukase [<xref
                                rid="B65-pharmaceuticals-13-00392" ref-type="bibr">65</xref>]. (<bold>a</bold>) LiOH,
                            THF/1,4-dioxane/H<sub>2</sub>O = 4/2/1, quantitative; (<bold>b</bold>) TFA; (<bold>c</bold>)
                            HCl.Et<sub>2</sub>O; (<bold>d</bold>) Peptide, HATU, Et<sub>3</sub>N, DMF/DMSO (1:1), 75%,
                            three steps; (<bold>e</bold>) 10% TFA/DCM; (<bold>f</bold>) 20% piperidine/DMSO; (<bold>
                                g</bold>) H<sub>2</sub>, Pd(OH)<sub>2</sub>, AcOH.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch007.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch008" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch008_Scheme 8</object-id>
                    <label>Scheme 8</label>
                    <caption>
                        <p>Synthesis of the PGN fragments <bold>54</bold> reported by Fukase [<xref
                                rid="B67-pharmaceuticals-13-00392" ref-type="bibr">67</xref>]. (<bold>a</bold>) TMSOTf,
                            CH<sub>2</sub>Cl<sub>2</sub>, −15 °C, MS 4Å, 20 min, 84%; (<bold>b</bold>) Me<sub>3</sub>N
                            BH<sub>3</sub>/BF<sub>3</sub>·Et<sub>2</sub>O, ACN, 1 h, 83%; (<bold>c</bold>)
                            [Ir(cod)H-(MePh<sub>2</sub>P)<sub>2</sub>]PF<sub>6</sub>, THF, 1.5 h; (d) I<sub>
                                2</sub>/H<sub>2</sub>O, 30 min, 81%; (<bold>e</bold>) CCl<sub>3</sub>CN/Cs<sub>2</sub>CO<sub>
                                3</sub>, DCM, 30 min, quantitative; (<bold>f</bold>) TMSOTf, DCM, MS 4Å, 40 min, 16%;
                            (<bold>g</bold>) Zn/Cu, AcOH,3 h, Ac<sub>2</sub>O/Py, 2 h, 62%; (<bold>h</bold>) LiOH,
                            quantitative. For the condensation: (<bold>i</bold>) WSCD/HOBt/DMF/TEA, HCl·<sc>
                                l</sc>-Ala-<sc>d</sc>-isoGln(OBn) or HCl·L-Ala-<sc>d</sc>-isoGln-<sc>l</sc>-Lys(Z)(OBn);
                            (<bold>j</bold>) HATU/DMF/TEA, HCl·<sc>l</sc>-Ala-<sc>d</sc>-isoGln-<sc>l</sc>-Lys(Z)-<sc>
                                d</sc>-Ala(OBn) or HCl·<sc>l</sc>-Ala-<sc>d</sc>-isoGln-<sc>l</sc>-Lys(Z)-<sc>d</sc>-Ala-<sc>
                                d</sc>-Ala(OBn); (k) H<sub>2</sub>/Pd(OH)<sub>2</sub>, AcOH.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch008.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch009" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch009_Scheme 9</object-id>
                    <label>Scheme 9</label>
                    <caption>
                        <p>Synthesis of the PGN fragment <bold>62</bold> reported by Marques [<xref
                                rid="B70-pharmaceuticals-13-00392" ref-type="bibr">70</xref>]. (<bold>a</bold>) (1)
                            PhCHO, ZnCl<sub>2</sub>, MS 3Å, r.t., overnight; (2) Ac<sub>2</sub>O, pyridine, r.t.,
                            overnight 78%; (<bold>b</bold>) morpholine, EtOAc, r.t., overnight, 87%; (<bold>c</bold>)
                            CCl<sub>3</sub>CN, Cs<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h,
                            74%; (<bold>d</bold>) BnOH, AcCl, 80 °C, 3 h, 61%; (<bold>e</bold>) PhCHO, ZnCl<sub>2</sub>,
                            overnight, 72%; (<bold>f</bold>) ethyl <sc>l</sc>-(<italic toggle="yes">S</italic>)-2-
                            trifluoromethanesulphonyloxy-propionate, NaH, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 3 h, 68%;
                            (<bold>g</bold>) Pd(PPh<sub>3</sub>)<sub>4</sub>, AcOH, TrocCl, r.t., 82%; (h) BH<sub>
                                3</sub>Me<sub>2</sub>N, BF<sub>3</sub>OEt<sub>2</sub>, r.t., 3 h, 72%; (<bold>i</bold>)
                            TMSOTf, DCM, MS 3 Å, -15 °C, 52%; (<bold>j</bold>) Zn-Cu, THF: AcOH: Ac<sub>2</sub>O
                            (1:1:1), then Ac<sub>2</sub>O/pyridine, 63%; (<bold>l</bold>) LiOH, THF:1,4-dioxane:H<sub>
                                2</sub>O, 69%; (<bold>m</bold>) Pd(OH)<sub>2</sub>, H<sub>2</sub>, AcOH, r.t.,
                            quantitative; (<bold>n</bold>) peptide coupling via Fmoc-solid-phase synthesis; (<bold>
                                o</bold>) TFA (1% CH<sub>2</sub>Cl<sub>2</sub>), r.t.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch009.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch010" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch010_Scheme 10</object-id>
                    <label>Scheme 10</label>
                    <caption>
                        <p>Reported multistep synthesis of NAG-NAM intermediates via orthogonal routes from
                            glucosamine.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch010.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch011" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch011_Scheme 11</object-id>
                    <label>Scheme 11</label>
                    <caption>
                        <p>Synthesis of the NAG-NAM precursor <bold>66</bold> from peracetylated chitobiose <bold>63
                        </bold> reported by Marques group [<xref rid="B79-pharmaceuticals-13-00392" ref-type="bibr">
                            79</xref>]. (<bold>a</bold>) Ac<sub>2</sub>O, H<sub>2</sub>SO<sub>4</sub>, 55 °C, 3 h, then
                            r.t., 16 h, and 55 °C, 1 h, 13%; (<bold>b</bold>) TFAA, Pyr, 120 °C, 15 min, 76%; (<bold>
                                c</bold>) TolSH, BF<sub>3</sub>OEt<sub>2</sub>, DCM, r.t., overnight, 80%; (<bold>
                                d</bold>) (1) MeONa, MeOH, r.t., overnight. (2) butane-2,3-dione, <italic toggle="yes">
                                p</italic>-TsOH, triethylorthoformate, EtOH, 60 °C, 16 h, 58%; (<bold>e</bold>) TBDMSCl,
                            DMAP, TEA, CH<sub>2</sub>Cl<sub>2</sub>, 56%; (<bold>f</bold>) (1) NaOH 2 M, THF, 80 °C, 3
                            h, (2) Ac<sub>2</sub>O, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 56%;
                            (<bold>g</bold>) (1) NaH, DCM, 30 min; (2) Ethyl (<italic toggle="yes">S</italic>)-2-(trifluoromethylsulfonyloxy)propionate,
                            r.t., 16 h, 38%.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch011.jpg"/>
                </fig>
                <fig id="pharmaceuticals-13-00392-sch012" orientation="portrait" position="float">
                    <object-id pub-id-type="pii">pharmaceuticals-13-00392-sch012_Scheme 12</object-id>
                    <label>Scheme 12</label>
                    <caption>
                        <p>Synthesis of NAG-NAM oligosaccharides (<bold>69</bold>) by Marques group [<xref
                                rid="B83-pharmaceuticals-13-00392" ref-type="bibr">83</xref>]. (<bold>a</bold>) Phthalic
                            anhydride, DMF 5% H<sub>2</sub>O, 120 °C, overnight; (<bold>b</bold>) <bold>C1</bold> (m =
                            1) or <bold>C2</bold> (m = 2), CDI, DMF, r.t., 24 h; (<bold>c</bold>) TBDMSCl, imidazole,
                            DMF, N<sub>2</sub>, r.t., 72 h; (<bold>d</bold>) (<italic toggle="yes">S</italic>)-2-chloropropionic
                            acid, NaH, DMF, r.t., 48 h; (<bold>e</bold>) (1) NH<sub>2</sub>NH<sub>2</sub>, H<sub>2</sub>O,
                            reflux, 24 h; (2) Ac<sub>2</sub>O, pyridine, r.t., overnight; (<bold>f</bold>) TBAF,
                            pyridine, r.t., overnight.
                        </p>
                    </caption>
                    <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait"
                             xlink:href="pharmaceuticals-13-00392-sch012.jpg"/>
                </fig>
            </sec>
        </back>
    </article>
</pmc-articleset>